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Summary  
The Epstein-%DUU YLUXV (%9 LV DQ RQFRJHQLF Ȗ-herpesvirus that establishes a life-
long infection in humans. It is ubiquitous in the population and is responsible for the 
development of multiple diseases including cancer. Analysis of the EBV DNA and 
RNA sequences has predicted that the viral genome encodes approximately 100 
protein-coding genes. However, the existence of many putative proteins has not 
been confirmed by biochemical methods yet. Furthermore, the identification of EBV 
open reading frames (ORFs) is difficult as viral genes are encoded on both strands of 
the double-stranded DNA genome and often overlap. Moreover, EBV encodes 
different types of non-coding RNAs.  
In order to identify the full scope of EBV’s coding capacity, ribosome profiling of 
replicating and non-replicating EBV strains was performed. Ribosome profiling 
combines classical ribosome footprinting experiments with current deep sequencing 
technology to map translating ribosomes on mRNA at single nucleotide resolution. 
This approach confirmed the majority of previously identified ORFs and has enabled 
the identification of 28 novel small open reading frames and of 8 alternative 
translation initiation sites.  25 of the 28 small ORFs were localized in the 5’leaders of 
several mRNA transcripts and are classified as upstream open reading frames 
(uORFs). Several of these uORFs were found to repress the translation of the 
downstream encoded main ORF.  
In summary, ribosome profiling of EBV-infected cells has allowed a comprehensive 
identification and annotation of the EBV ORFs and has revealed a novel mode of 
viral gene expression regulation at the translational level.  
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Zusammenfassung  
Das Epstein-Barr-Virus (EBV) ist ein onkogenes Virus, das eine lebenslange 
Infektion im Menschen etabliert. Es ist allgegenwärtig in der menschlichen Population 
und trägt zur Entstehung von mehreren Krankheiten bei, unter anderem auch Krebs. 
Die Analyse der EBV DNA und RNA Sequenzen hat vorhergesagt, dass das virale 
Genome ungefähr 100 proteinkodierende Gene enthält. Die Existenz vieler dieser 
putativen Proteine ist jedoch noch nicht mit biochemischen Methoden bestätigt 
worden. Zudem ist die Identifizierung von EBVs offenen Leserahmen (OLRs) 
schwierig, da virale Gene auf dem doppelsträngigen DNA-Genom auf beiden 
Strängen und oft überlappend kodiert sind. Darüber hinaus enthält EBV 
verschiedene Arten von nicht-kodierenden RNAs.  
Um die gesamte Kodierungskapazität des EBV Genoms zu identifizieren, wurden 
Ribosomenprofile von replizierenden und nicht replizierenden EBV Stämmen erstellt.  
Ribosomenprofile verbinden klassische “ribosome footprinting” Experimente mit 
aktuellen Hochdurchsatzsequenzierungstechnologien, um translatierende 
Ribosomen auf Nukleotidebene auf mRNA zu identifizieren. Diese Methode 
bestätigte the Mehrheit der zuvor beschriebenen viralen OLRs und hat die 
Identifizierung von 28 neuen, kleinen offenen Leserahmen sowie 8 alternativer 
Translationsstart ermöglicht. 25 der 28 OLRs waren auf mRNAs im 5’Bereich vom 
Hauptleserahmen unterschiedlicher Gene lokalisiert. Für einige dieser kleinen OLRs 
konnte eine repressive Funktion auf die Translation des nachgeschalteten Gens 
nachgewiesen werden.  
Zusammenfassend haben Ribosomenprofile von EBV-infizierten Zellen eine 
umfangreiche Identifizierung und Annotation der EBV OLRs ermöglicht. Zudem 
wurde eine neue Regulationsweise der viralen Genexpression auf Translationsebene 
aufgezeigt.    
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1. Introduction 
 
1.1. EBV is an oncogenic herpesvirus 
Herpesviruses are a diverse group of DNA viruses. More than 100 herpesviruses 
have been described to date. Epstein-Barr virus (EBV) is classified as a human 
herpesvirus and belongs to the gammaherpesvirus subfamily. Within the systematic 
nomenclature established for human herpesviruses EBV is known as human 
herpesvirus 4 (HHV-4).  
EBV was the first virus described as an etiologic agent for human tumors. In 1958 the 
pathologist Denis Burkitt firstly described multifocal lymphomas in the jaws of young 
children born and living in Sub-Saharan Africa. The epidemiological features of this 
tumor led him to hypothesize an infectious agent as the driving force for the disease. 
This led to the discovery of EBV, which was isolated and described by Sir Michael 
Epstein, Yvonne Barr and Bert Achong1.  
EBV infects about 90-95% of the world’s population2,3. The infection is asymptomatic 
in most individuals4. It is known as a frequent causative agent of an infectious 
mononucleosis syndrome and is estimated to cause up to 2% of tumors worldwide5.  
 
1.1.1. EBV particle structure  
The structure of the EBV particle is shown  schematically in figure 1.1. The outermost 
layer of the particle is a host cell-derived lipid envelope with viral glycoproteins 
embedded within it6.  
 
 
Figure 1.1. EBV particle structure. a. A schematic overview of the EBV particle is depicted. See text for details. 
b. Electron micrograph of an EBV particle. The electron-dense area contains the viral DNA genome. The EM 
image was taken from: Pavlova et al. 20137.  
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Beneath the lipid layer of the virion is the tegument. The tegument is filled with RNA 
and protein complexes of viral (the tegument proteins) and cellular origin6,8. These 
proteins modulate the infection process.  
The tegument layer surrounds an icosahedral nucleocapsid composed of 162 
capsomeres6. The capsid surrounds the linear, double-stranded DNA (dsDNA) 
genome. The genome is wrapped around a toroid-shaped protein core6.  
 
1.1.2. EBV genome structure 
The size of the dsDNA genome ranges from 172 to 186 kb6. As with other 
herpesviruses the genome of EBV can be divided into the unique short region (US) 
and the unique long region (UL)9 (Figure 1.2.). Between these two domains lies a 
segment consisting of an internal direct repeat domain (IR1). Moreover, the UL 
domain is subdivided into smaller segments (U2-U5) by further internal direct repeat 
domains (IRs)6.  The genome is flanked by 0.5 kb long terminal repeats (TRs). The 
number of TRs varies between different viruses10. The variation comes from the 
random recombination of the TRs during genome circularization.  
 
Figure 1.2. The linear US/UL organization of the EBV genome. TR: terminal repeat. US: unique short region. 
UL: unique long region. OriP: origin of plasmid replication. OriLyt: origin of lytic replication. IR1-4: internal direct 
repeats. 
 
The origin of plasmid replication (oriP) maintains the episome in the infected cell. 
During virus particle production, also known as lytic replication, the viral DNA is 
copied from two origins of lytic replication (oriLyt) within the UL domain.  
The nomenclature for EBV open-reading frames (ORFs) is derived from the analysis 
and characterization of the B95-8 genome after BamHI restriction enzyme digestion 
(Fig. 1.3.). Each EBV transcript in the viral genome was given a name based on the 
location within one of the BamHI restriction fragments. For example: the gene BZLF1 
is the acronym for a gene localized in the BamHI Z fragment with a leftward oriented 
open reading frame11. Since it is the first open reading frame in the Z fragment it 
carries the number 1.  
! )!
 
Figure 1.3. Organization of the viral genome according to BamHI restriction enzyme digestion. The BamHI 
restriction fragments are shown in the B95-8 genome. Restriction fragments are named according to their size 
with A being the largest fragment. The diagram indicates the location of viral latent proteins. In addition to the 
conventional BamHI fragment-derived nomenclature these proteins also have an alternative nomenclature as 
shown here. TR: terminal repeat. OriP: Origin of plasmid replication. Image was taken from: Young et al. 200312.  
 
EBV-encoded genes are divided into two broad categories. The first category 
comprises the lytic genes which are responsible for virus particle production. The lytic 
genes are further subdivided into immediate early (IE) genes that initiate the lytic 
cascade, the early (E) genes that replicate the viral genome and the late (L) genes 
that constitute and assemble the virions.  
The second category comprises the latent genes. Latent genes are expressed in 
infected cells that do not replicate. These cells are termed latently infected cells. The 
latent genes mediate the establishment of a persistent infection in the host. The 
number of latent genes expressed in latently infected cells varies and depends on the 
infected cell type. This leads to a variety of virus-host interactions that have different 
consequences for the infected cell. The latent genes are divided into two sub-types: 
(i) the Epstein-Barr nuclear antigens (EBNA) and (ii) the latent membrane proteins 
(LMPs). The EBNA family of proteins consists of: EBNA-LP, EBNA1, EBNA2, 
EBNA3A, EBNA3B and EBNA3C.  These proteins maintain the viral genome in 
infected cells and activate viral and cellular transcription. The LMP proteins comprise: 
LMP1, LMP2A and LMP2B. LMP1 is a transmembrane protein mimicking constitutive 
CD40 signaling13. LMP2A confers constitutive B cell receptor (BCR) signaling14. 
LMP2B lacks the first coding exon of LMP2A and regulates LMP2A activity. 
The expression of the complete set of the latent genes leads to active proliferation in 
infected B cells. This state is known as full latency.   
Apart from protein-coding genes EBV also encodes several non-coding RNAs. The 
most abundant are the two Epstein-Barr virus encoded small RNAs (EBERs) EBER1 
and EBER26. They are localized in the nucleus15. Both EBER RNAs are reported to 
! *!
interact with the La antigen15 and EBER1 has been found to interact with the 
ribosomal protein L2216,17. Furthermore, EBER2 has recently been described to 
localize to the TRs of the viral genome and thereby modulate LMP2 expression18.   
EBV further encodes 44 mature micro-RNAs (miRNAs)19,20 (reviewed in Klinke et al. 
201421). These are 19 to 25 nucleotides long non-coding RNAs involved in regulation 
of protein expression in infected cells. The miRNAs are grouped into two separate 
clusters within the EBV genome (Fig. 1.4.). The first miRNA cluster is located around 
the BamHI fragment H rightward open reading frame 1 (BHRF1) ORF and it encodes 
four miRNAs (Fig. 1.4.). The second cluster in the BamHI fragment A rightward 
transcript (BART) encodes all remaining miRNAs arranged in two sub-clusters 
(cluster I and cluster II) and one seperately encoded miRNA (miR-BART2)22 (Fig. 
1.4). BHRF1 miRNAs are important factors for EBV-mediated transformation of B-
cells23-25. Some BART miRNAs are reported to limit lytic replication in infected 
cells26,27.  
EBV has also been reported to encode a small nucleolar RNA (v-snoRNA1)28. 
Recent computational analysis of small RNA sequencing data has identified a stable 
intronic sequence RNA (sisRNA) encoded within the W repeats of the EBV 
genome29.  
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Figure 1.4. EBV-encoded miRNAs. Schematic illustration of the genomic regions encoding EBV miRNAs. Four 
miRNAs are encoded around the BHRF1 gene. One miRNA is processed from the 5’leader of the transcript while 
the other two are encoded in the 3’untranslated region of the gene. The BamHI A genomic region encodes the 
majority of the viral miRNAs that are derived from the introns of the highly spliced BamHI A rightward transcripts 
(BARTs). For the BART miRNAs only one of the miRNAs of the pre-miRNA duplex are listed but both strands of 
the processed pre-miRNA transcript can be loaded into the RNA-induced silencing complex.  
 
1.1.3. The EBV transcriptome 
Viruses in general are known for the efficient utilization of the coding capacity 
dictated by their genome sizes. Herpesviruses exploit this principle to the fullest and 
have evolved to use the limited coding space optimally. RNA sequencing 
experiments have highlighted the complex transcriptome of EBV30,31. Genes are 
transcribed from both DNA strands and frequently overlap32. Non-canonical 
transcription initiation is often used among lytic genes and many genes possess 
alternatively spliced isoforms33. Furthermore, a recent publication has identified close 
to 300 new EBV transcripts that are produced upon lytic replication initiation33. These 
transcripts are in addition to the already annotated EBV transcripts.  
 
1.1.4. The viral glycoproteins determine cell tropism 
The viral lipid envelope harbours multiple glycoproteins which play a role in virus 
attachment, entry and egress. The gp350/220 glycoproteins mediate virus 
attachment to particular target cells. Gp110 (gB), gp85 (gH) and gp25 (gL) build up 
the core fusion complex. The gp42 can interact with gH/gL. It further interacts with 
human leukocyte antigen (HLA) class II. BMRF2 is a glycoprotein that contains an 
arginine-glycine-aspartate (RGD) motif which is a motif used by extracellular matrix 
proteins to bind to integrins34,35. Integrins are transmembrane proteins expressed on 
cells that mediate the cell-cell or cell-extracellular matrix contact35. Different 
combinations of the viral glycoproteins are necessary to infected different cell types.  
The cell tropism of EBV is broad. EBV is reported to infect human B cells, epithelial 
cells, NK cells and T cells36-38.  
EBV readily infects B cells in vitro and B cell infection by EBV is best studied 
compared to the other described target cells6. Infection of the host’s B cells occurs 
through the interaction of viral gp350/220 receptors with the cellular CD2139-41 or 
CD35 proteins42. Both proteins are complement receptors on B cells. The attachment 
of the virus to the target cell via CD21 leads to endocytosis of the particle. 
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Additionally the viral gp42/gH/gL trimer interacts with cellular MHC class II molecules 
and integrins to mediate fusion43.  
Epithelial cells are difficult to infect in vitro. Infection experiments with primary 
epithelial cells report less than 0.1% of cells being infected with EBV44,45. The 
receptors used for viral B lymphocyte infection are only expressed at low levels on 
epithelial cells46,47. In vitro studies have shed some light on the infection process by 
using EBV mutants that are devoid of specific glycoproteins. In epithelial cell infection 
gp350 and gp42 are not needed. The gH/gL complex on the other hand is 
essential48. Treatment of viruses with gH/gL neutralizing antibodies reduces virus 
binding to epithelial cells. Furthermore, a recent publication by Wang et al. has 
identified neuropilin 1 (NRP1), a co-receptor for growth factors, as an interaction 
partner of gp110 and mediator of viral entry into epithelilal cells49. Additionally, 
BMRF2 is important for epithelial cell infection. The protein interacts with integrins 
and mediates the infection on the basolateral side of polarized epithelial cells34.  
A significantly higher infection efficiency can be achieved by using transfer infection. 
Transfer infection involves EBV bound to naïve B cells that can transfer the virus to 
epithelial cells50. The crosslinking of the CD21 protein on the B cell surface leads to 
activation of adhesion molecules on the cell45. This enables the formation of a 
virological synape between the B cell and epithelial cell that facilitates infection45. The 
percentage of EBV+ epithelial cells after transfer infection is reported to reach 20% of 
the culture.  
Entry of the virion proceeds in epithelial cells at the cell surface. No prior endocytosis 
is involved.  
Once infection is successful, 20-40% of the infected epithelial cells will enter lytic 
replication within days following infection51-53. Long-term culture of EBV-infected 
epithelial cells has so far only been demonstrated in telomerase reverse 
transcriptase-immorzalized epithelial cells that carry an additional deletion of the 
cyclin-dependent kinase inhibitor p16 or overexpress cyclin D154,55. Tsang et al. have 
shown that EBV-infected epithelial cells arrest growth after some time due to the 
activity of the cyclin-dependent kinase inhibitor54. By deregulation of one of the cell 
cycle regulators the infected cells will continue proliferating.  
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1.1.5. Lytic replication  
Lytic replication is necessary to generate progeny virions that spread the infection to 
other individuals and replenish the pool of infected cells.  
Lytic replication begins with the expression of two immediate early genes; the lytic 
transactivators: BZLF1 (also known as Z or Zta) and BRLF1 (also known as R or 
Rta)56,57. These two proteins bind to lytic promoters in the viral genome and activate 
the lytic replication cycle6.  
The viral episome is replicated by the cellular DNA replication machinery during 
latency. Once lytic replication is initiated, the viral genome is replicated by the early 
lytic proteins. These include: BALF5, the viral DNA polymerase, BSLF1, the viral 
primase and BMRF1, the polymerase processivity factor. The genome is replicated 
by the rolling circle method as a large concatemer that is then cleaved within the TR 
regions to generate individual EBV genomes that can be packaged into 
nucleocapsids58,59.  
Genome replication is also needed for the production of the late lytic genes which are 
transcribed from newly replicated DNA60. For example, the glycoprotein gp350 is not 
expressed in lytically replicating cells that have been treated with phosphonoacetic 
acid which inhibits the viral DNA polymerase and prevents viral genome replication61.  
Nucleocapsid assembly occurs in the nucleus. From there the nucleocapsid passes 
through several cellular membranes with multiple envelopment and de-envelopment 
proccesses taking place. Viral proteins such as BFRF1 direct this virion maturation 
process62. The mature virion is released from Golgi-derived vesicles at the plasma 
membrane63. 
Analysis of fractioned tonsils shows that EBV replicates in differentiated plasma cells 
in vivo64. This is supported by histological analyses65,66.  
Apart from terminal differentiation, stress can also trigger lytic reactivation  in infected 
cells. The link between stress-inducing agents and lytic replication has mainly been 
studied in vitro. Agents triggering lytic replication include chemotherapeutics and 
hypoxia67. Stimuli that engage certain pathways such as TGF-ȕ VLJQDOLQJ FDOFLXP-
associated pathways or B cell receptor signaling also lead to reactivation (discussed 
in: Amon et al. 2005 and Tsurumi et al. 200568,69). Many lytic replication inducers can 
also be found in our daily environment. Some lytic cycle inducing agents are for 
example, phorbol esters, n-butyrate and nitrosamines present in preserved or grilled 
food.  
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1.1.6. B cell transformation in vitro 
Naïve B cells can readily be infected with EBV in vitro. As the virus enters the cell, 
the crosslinking of CD21 triggers intracellular signaling that causes the cell to 
transition from G0 into the G1 phase of the cell cycle70. Upon infection a “pre-latent” 
state is induced within the affected B cells. Before the viral DNA is transcribed, viral 
transcripts can already be detected which are probably delivered by the virions71,72. 
This mRNA cargo allows immediate expression of viral proteins72,73. Here, 
expression of a subset of lytic genes in parallel to latent genes occurs74,75. The 
earliest latent transcripts detected are EBNA2 and EBNA-LP76,77. The lytic viral 
genes transcribed are BHRF1, an anti-apoptotic bcl-2-like protein78, the viral 
transactivators BZLF1 and BRLF179,80, the viral immune evasion proteins (BALF1, 
BCRF1, BNLF2a) and BMRF1, the viral processivity factor72. This early event of lytic 
replication is not well understood and the relevance of it still remains to be 
elucidated. Once the pre-latent stage is overcome and the viral DNA has entered the 
nucleus the cells progress to latency.  
The first latency stage is latency IIb. This stage directs the initial round of cell division 
after infection81. Latency IIb is characterized by the additional expression of EBNA1, 
EBNA3A, EBNA3B, EBNA3C, the EBER transcripts and viral miRNAs. The infected 
cell then transits to the latency III stage also known as the growth program82. In 
latency III the complete set of latent genes is produced6,76,83,84. These include the 
LMP1, LMP2A and LMP2B proteins. In vitro infected cells stay in latency III and 
continue proliferating indefinitely as immortalized lymphoblastoid cell lines (LCLs).  
In vivo the infection process of EBV is more complex and is discussed in the 
following chapter. 
 
1.1.7. EBV infection of the host 
EBV spreads and enters the host via saliva85. The virus crosses the epithelial barrier 
in the region of the Waldeyer tonsillar ring in the nasopharynx, probably by 
transcytosis86. Another model proposes that the virus infects the epithelium of the 
Waldeyer tonsillar ring in the oropharynx and is then amplified through lytic 
replication. The second model is somewhat disputed as there is evidence that 
epithelial cells are resistant to EBV infection from the mucosal side of the 
epithelium34.  Once the viral particles have passed the epithelial barrier, they go on to 
infect naïve B cells situated in the underlying lymphoid tissues.  
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Following infection the B cells progress through the same latency stages as 
described in section 1.1.6. Primary EBV infection is countered by a strong immune 
response in the host. Therefore, infected cells do not stay in latency III but 
progressively downregulate the viral gene expression in order to avoid destruction by 
the immune system87-89.  
Latency III in vivo is active for about three days and closely mimicks the initial burst 
of proliferation of antigen-activated B cells in germinal centers (GC)90,91.  Once 
infection is successfully established viral gene expression is sequentially silenced 
until the infected B cell is virtually invisible to the host’s immune system. For that to 
occur the infected cells migrate to the follicle of the lymph node and initiate a GC 
reaction.  
In the GC, the infected cells switch to the default transcription program also termed 
latency IIa. Latency IIa rescues the infected cells from the GC and allows them to 
differentiate into memory B cells. Infected B cells that have entered the GC 
phenotypically resemble true GC B cells. They express the characteristic surface 
markers (CD10+, CD77+, CD38+), chemokine receptors (CXCR4, CXCR5 and no 
CCR7) as well as the GC specific proteins: AID and bcl-692. Within the GC only a 
subset of latent proteins are expressed: EBNA1, LMP1 and LMP26,93. EBNA1 is 
essential to ensure proper segregation of the episome to daughter cells as well as to 
recruit the cellular replication machinery to the viral genome during S phase94. LMP1 
and LMP2 provide the necessary survival signals to enable the transition from GC to 
memory B cell.  
Following memory B cell differentiation the infected cells switch to latency 0. Latency 
0 is characterized by complete absence of viral protein expression95,96. This protects 
the virus from immune surveillance and allows long-term viral persistence.  
Occasionally, the infected resting memory B cell will divide and the latency I program 
is initiated that expresses EBNA1 only.  
Genes expressed during the different latency stages are summarized in figure 1.5.  
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Figure 1.5. EBV latency states during EBV infection. The figure summarizes the different latency states 
observed during EBV infection. The viral genes expressed during each latency stage are listed below and 
classified as non-coding RNAs (EBERs and miRNAs), latent genes or lytic genes.  
 
1.1.8. EBV strain heterogeneity 
The first EBV strain to be sequenced was B95-811. It was at that time the only strain 
in culture that produced enough virus to allow for restriction enzyme analysis and 
subsequent cloning of these fragments for sequencing. Originally, B95-8 was derived 
from a spontaneous human LCL arising from an IM patient97. It was used to 
transform lymphocytes of the cotton top marmoset and the infected cells produced 
EBV spontaneously in vitro. This virus was then used to transform B cells and the 
resulting LCLs could be induced into lytic replication by treatment with phorbol esters 
and n-butyrate. Samples used for sequencing were produced by this chemical 
induction method98. The B95-8 strain has for a long time been used as the prototypic 
laboratory strain despite a 13.6 kb deletion within its genome in comparison to other 
EBV strains99. This deletion alters the expression of some genes100. Moreover, it is 
missing a large part of the EBV viral miRNAs101 that have been described to 
influence cell growth, cell cycling and lytic replication. 
The advent of cheaper whole-genome DNA sequencing has now made it possible to 
study EBV isolates and geographic variation on a larger scale. Palser et al. have 
sequenced and published 71 new EBV strains isolated from healthy EBV carriers and 
from multiple primary tumors taken from several distinct geographic regions102. They 
described several polymorphisms across viral open reading frames. The strongest 
polymorphisms were located within latent genes. Yet, their study makes no 
conclusions on possible links between the studied genotypes to observed 
phenotypes.  
Most EBV genes have a sequence identity of about 90 - 95% between different 
isolates. EBNA2 on the other hand only has a sequence identity of 70% at nucleotide 
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level and 54% at protein level. This polymorphism was used early on to classify EBV 
isolates into type 1 or type 2 based on the EBNA2 gene sequence6. It was the first 
classification of EBV isolates that correlated a viral gene sequence to a phenotypic 
trait in infected cells. Type 1 EBV transforms B cells readily into LCLs, type 2 EBV on 
the other hand is less efficient103. EBV type 1 is also the prevalent strain in the world. 
In sub-Saharan Africa, type 2 is equally abundant and mixed infections occur 
frequently. Type 2 is also often found in individuals suffering from some kind of 
immune-incompetence (due to immunosuppression in transplant recipients or 
immune ablation in HIV+ patients)104-108. 
A recent study linking viral polymorphisms and the phenotypic behaviour of the virus 
stems from the characterization of the M81 EBV strain, a virus isolate retrieved from 
a nasopharyngeal carcinoma (NPC) patient in China109.  
The M81 isolate was derived from a NPC biopsy of a Chinese patient110. It was 
recently cloned into a bacterial artificial chromosome (BAC) and characterized in 
greater detail109. The virus exhibits reduced B cell tropism compared to B95-8 but 
infects epithelial cells at higher efficiency109. Infection of B cells with the M81 strain 
leads to the initiation of spontaneous lytic replication in cell culture in 3-6% of infected 
LCLs at around 3 weeks post infection109,111. Infectious virus is produced even 
though most is found to be bound to neighboring LCLs. In comparison, the B95-8 
strain does not mount lytic repication in vitro.  
Genetically M81 and B95-8 are quite distant. Most viral genes harbor several 
polymorphisms. Tsai et al. used B95-8 and M81 to construct hybrid viruses by 
exchanging the BZLF1 open reading frame and promoter from M81 with the one from 
B95-8. BZLF1 is a viral transactivator that upon expression initiates lytic replication in 
EBV-infected cells.The study showed that the BZLF1 gene was one of the genes 
contributing to the described phenotype of M81.  
 
1.1.9. EBV-associated malignancies  
EBV infects humans all over the world. Nevertheless, some EBV-associated 
diseases are preferentially encountered in specific geographic regions. Furthermore, 
these diseases range from benign to malignant tumors. Especially in 
immunocompromised individuals the virus can be the cause of severe disease. Some 
of the EBV-associated cancers include endemic Burkitt’s lymphoma (eBL), Hodgkin’s 
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lymphoma, NK/T-cell lymphoma36, nasopharyngeal carcinoma (NPC) and gastric 
carcinoma.  
The genetic background of the host, co-infecting pathogens, local diet and life-style 
habits such as smoking are reported to influence the development of certain EBV-
associated diseases112. Moreover, several of EBV-associated cancers are 
accompanied by increased titers to lytic antigens. This indicates that ongoing and 
badly controlled virus replication could cause disease development. Support for lytic 
replication as a risk factor comes from a recent publication reporting that viral lytic 
genes are frequently co-expressed with cellular cancer-associated pathways113. 
Furthermore, there is a possibility that these diseases might be linked to particular 
EBV strains. 
It is outside of the scope of this thesis to describe all EBV-associated malignancies. 
Therefore, three EBV-associated diseases will be discussed briefly: (i) infectious 
mononucleosis, (ii) endemic Burkitt’s lymphoma and (iii) nasopharyngeal carcinoma. 
 
Infectious mononucleosis  
EBV can cause an infectious mononucleosis syndrome (IM). IM is characterized by a 
benign expansion of B lymphocytes in the presence of high fever as well as a sore 
throat and fatigue. The disease is usually self-limiting and IM patients recover 
completely. In rare cases, it can affect the liver causing hepatitis and in the worst 
case liver failure. EBV-associated IM is often caused by a delayed primary EBV 
infection114. The age of primary EBV infection has shifted into adolescence in the 
developed countries115-119. While by adulthood almost all individuals are seropositive 
for EBV, the prevalence in young children is much lower, ranging from 20 to 80% 
depending on age group, geographic region and ethnicity115-117,120,121. This late 
encounter with EBV puts affected individuals at greater risk for IM during primary 
infection122. The reasons for this are not understood. The disease itself mainly stems 
from the inflammatory response triggered by the infection and once symptoms occur 
the infection is already residing123.  
 
Endemic Burkitt’s lymphoma 
Endemic Burktit’s lymphoma (eBL) was the first human cancer linked to a viral 
infection. EBV is detected in approximately 95% of eBL cells124. The disease is 
geographically restricted to the malaria belt of the world implying that there is a 
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correlation between malaria prevalence and the development of this disease6,124. 
Studies show that patients treated for malaria have high EBV blood titers125. The 
hallmark of eBL is deregulated expression of the c-myc oncogene due to a 
translocation with immunoglobulin genes126-128. This translocation has been shown to 
be sufficient in causing Burkitt’s lymphoma in mice129. EBV is clonal in eBL hinting 
that the virus was already present before the translocation occurred and the 
lymphoma developed130.  
 
Nasopharyngeal carcinoma 
The WHO has classified NPC into 3 subtypes based on their differentiation state. 
EBV can be found in all three subtypes131 but has a 100% association with the 
undifferentiated type132. The tumor has a high geographic restriction mainly occurring 
in Southeast Asia, Northern Africa and Alaska6.  
A hallmark of NPC are the increased antibody titers to EBV133-135. They increase as 
the disease progresses and are mainly directed against lytic antigens136,137.  
The M81 strain described in the previous chapter exhibits increased epitheliotropism 
and propensity to initiate lytic replication in infected cells. Both features are 
prerequisites for disease development. This supports the hypothesis that distinct 
EBV strains cause specific EBV-associated diseases109. Moreover, other EBV strains 
isolated from NPC patients cluster together with M81 in phylogenetic analyses.  
The intrinisic characteristics of the NPC-derived viral strains together with 
environmental factors such as diet, might promote the development of the disease.  
Several studies have reported a link between the consumption of preserved food, 
containing high levels of phorbol esters and nitrosamines, and the development of 
NPC138-140. Campaigns against preserved foods have lead to a drop of NPC 
incidence rates in these populations141. Different Chinese herbs used in traditional 
medicine142, work-related exposure to toxic dust as well as fumes and smoking143,144 
have also been identified as risk factors for NPC. Furthermore, a genetic component 
is involved as NPC incidence is seen clustered in families145,146. 
 
  
! "*!
1.2. Translation in mammalian cells  
Gene expression in mammalian cells is controlled on multiple levels starting in the 
nucleus with the modulation of transcription. Protein abundance is further regulated 
by altering transcript levels through degradation pathways and sequestering mRNAs 
in specialized storage granules (Fig. 1.6). Finally, protein levels are directly controlled 
by the translation rate of the mRNA and protein turnover. Translation is a dynamic 
process and studying the translatome, the RNAs that are translated at a given 
timepoint in a cell, enables the distinction between transcripts that are physiologically 
important and the ones that constitute transcriptional noise.  
In the next paragraph, I will describe the molecular and regulatory mechansisms that 
enable protein expression in mammalian cells.  
 
Figure 1.6. Post-transcriptional gene expression control. An overview over the main processes that lead to 
protein expression. Upon transcription in the nucleus the mRNA is exported into the cytoplasm. Here the mRNA 
can be destined to one of three pathways: (i) the mRNA associates with the translation machinery and leads to 
the production of protein, (ii) the mRNA is stored in specialized RNA granules or (iii) the mRNA is degraded. Each 
step contributes to the regulation of protein abundance in a cell. Protein abundance is further controlled by protein 
turnover rate.  
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1.2.1. Translation initiation  
Translation can be divided into three distinct parts: (i) initiation, (ii) elongation and (iii) 
termination147. All three stages are regulated although in general, translation is 
primarily regulated at the initiation stage as this is said to be the rate-limiting step148.  
 
(i) Initiation:  
In eukaryotic cells the vast majority of translated mRNA is cap-dependent, meaning 
that the production of functional protein requires a complex that assembles on the 7-
methylguanosine cap at the 5’ end of the transcript (Fig. 1.7)147,148. This complex is 
termed eukaryotic initiation factor 4F (eIF4F) and consists of the cap-binding protein 
eIF4E, the scaffold protein eIF4G and the RNA helicase eIF4A. It is responsible for 
regulating ribosome attachment and protein synthesis. At initiation, the 40S ribosomal 
subunit interacts with eIF3, which is bound to eIF4G. Here the 40S subunit forms a 
ternary complex with eIF2, the initiator transfer RNAmet and GTP, which in turn 
associates with eIF1, eIF1A and eIF3 to form the 43S preinitiation complex that 
scans the 5’ leader region of the mRNA until it encounters a start codon. 
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Figure 1.7. Cap-dependent translation initiation. A schematic of canonical translation initiation in mammalian 
cells is shown. a. A simplified view of a mRNA transcript is depicted. The 5’cap (7mGpppG) and poly(A)-tail are 
included. The AUG start codon of the open reading frame is boxed in green. b. The translation of a mRNA begins 
with the assembly of three of the eukaryotic translation initiation factors (eIFs) on the mRNA cap: the eIF4E (cap-
binding protein), eIF4G (scaffold protein) and eIF4A (RNA helicase). These three proteins constitute the eIF4F 
complex. c. Assembly of the eIF4F complex on the cap leads to the binding of the small ribosomal subunit (40S). 
The 40S subunit is complexed with further initiation factors that make up the 43S pre-initiation complex. This 
complex scans the mRNA until it encounters a start codon in the right sequence context fit for initiation. d. Once a 
start codon is encountered, the 60S ribosomal subunit joins and with the 40S subunit the 80S translation-
competent ribosome is formed. This enables the translation of the open reading frame. e.  Translation initiation 
factors dissociate from the 80S ribosome and are replaced by elongation factors (not shown here).  
 
Subsequently, eIF5 is recruitHG DQG WULJJHUV K\GURO\VLV RI WKH H,)Į-bound GTP, 
thereby facilitating release of the initiation factors from 40S and allowing the 
association of the 60S ribosomal subunit to form the elongation-competent 80S 
ribosome. The initiation codon AUG in the context of a strong Kozak consensus 
sequence is the most efficient site for 80S ribosome assembly149. The Kozak 
consensus sequence is a particular nucleotide sequence surrounding the start codon 
that determines the efficiency of start codon recognition by the ribosome149-151 
(Fig.1.8). It was identified by mutagenesis studies and subsequent sequence 
analysis of 699 vertebrate mRNAs149,152. The adenosine base of the start codon AUG 
is numbered as +1. If one of the crucial bases does not match, the Kozak sequence 
is classified as intermediate. If there is no match on both of the consensus bases, 
then the Kozak sequence is classified as weak.  
If the AUG is in a suboptimal Kozak sequence context, the scanning 43S preinitation 
complex can skip it. This process is called leaky scanning151,153. Once the ribosome 
begins translation of the ORF, the initiation factors dissociate and are replaced by 
eukaryotic elongation factors (eEFs).  
 
 
Figure 1.8. The Kozak consensus sequence. A schematic depiction of the Kozak consensus sequence is 
shown. The AUG start codon is highlighted in green. The crucial bases determining the Kozak sequence strength 
are shown in orange. The adenine base (A) of the AUG start codon is referred to as base position +1. The base in 
position -3 is either of the purine bases adenine (A) or guanine (G). The base in position +4 is ideally a G. 
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(ii) elongation: 
Translation is mainly regulated at the initiation step147 but there have also been 
reports showing that translational control and fine tuning can occur at the step of 
elongation154-156.  
During elongation eEF1A delivers aminoacyl tRNAs to the ribosome’s A site for 
peptide bond formation. eEF2 mediates the translocation process following the 
peptide bond formation. Elongation continues until a stop codon is encountered.  
 
(iii) termination:  
Stop codons are recognized by the eukaryotic release factor eRF1 which then 
induces hydrolysis of the tRNA bound to the new polypeptide157. eRF3 removes 
eRF1 and the ribosome dissociates into the 40S and 60S subunits.  
 
Apart from cap-dependent translation, a cap-independent internal ribosome entry site 
(IRES) can be used for initiation. Here, the 40S subunit can directly bind to the 
mRNA close to the start codon by recognizing a specific RNA secondary structure. 
This was first described in viral protein synthesis of picornaviruses158,159 but has also 
been identified in other viruses such as Hepatitis C Virus (HCV)160 and EBV161. IRES-
mediated translation initiation is also used by cellular genes such as BiP162, VEGF163 
and c-myc164,165. Currently, 10% of mammalian mRNAs are predicted to contain an 
IRES166,167. These elements are particularly important during mitosis, cell 
differentiation or cell stress when cap-dependent translation is compromised. 
 
1.2.2. Translation regulation through 5’leaders of mRNAs 
Translation is a highly energy-consuming process and thus needs to be carefully 
regulated in cells. Furthermore, control of protein production on the level of 
translation gives the cell a lot of flexibility allowing it to respond to signaling cues 
almost immediately. Translation is regulated by controlling the abundance of initiation 
factors and the availability of ribosomes147,148.  
Protein expression can further be regulated through several mechanisms guided by 
cis-acting elements encoded on the mRNA itself. These regulatory elements have 
been described in the 5’leaders and 3’untranslated reagions (UTRs) of mRNA 
transcripts. I will focus here only on the regulation mediated by the 5’leader.  
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Figure 1.9. Cis-acting regulatory elements in the 5’leaders of mammalian mRNAs. A schematic depiction of 
the regulatory elements identified in the 5’leaders of mammalian mRNAs. The 5’leader can encode several 
elements that affect the downstream translation of the main open reading frame (mORF). From left to right: stable 
hairpin structures can stall the 43S preinitiation complex from scanning the mRNA. Internal ribosome entry sites 
(IRES) direct cap-independent translation and preclude scanning of the mRNA. RNA-binding proteins (RBP) bind 
to sequence-dependent sites on the mRNA transcripts and regulate mRNA stability and translation rates. 
Upstream open reading frames (uORFs) are small open reading frames in the 5’leaders that modulate the 
translation of the mORF. 7-meGpppG: 7-methylguanosine cap.  
 
Secondary structures 
Within the 5’leader, particular nucleotide compositions can favour the formation of 
stable secondary structures such has hairpins (Fig. 1.9)168. Especially GC-rich 
sequences form complex structures that can inhibit or stall 43S preinitiation 
movement within the transcript leader150,169-171.  
 
RNA-binding proteins  
RNA-binding proteins (RBPs) interact with specific RNA sequences present in the 
5’leaders and 3’UTRs of mRNA transcripts. Their binding can directly affect the 
stability and translation rates of mRNAs (Fig. 1.9)172-174.  
 
Upstream open reading frames  
Upstream open reading frames (uORFs) are short open reading frames localized 
within the 5’leaders of mRNA transcripts (Fig. 1.9)175. They are common in mRNAs 
coding for proteins that need to be tightly controlled in their expression level. These 
include oncogenes, cell differentiation factors, growth factors and cell cycle 
proteins176,177. The short ORFs interfere with the translation of the downstream 
encoded main ORF (mORF)178,179. UORFs regulate translation by either of the 
following mechanisms (Fig. 1.10): 
1. Upon translation of the uORF the ribosome dissociates and does not reach the 
mORF (Fig. 1.10b)180-182.  
2. The uORF encodes a functional peptide and upon translation the peptide inhibits 
progression of the ribosome (Fig. 1.10c)183-185.   
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3. In a subset of uORF-encoding mRNAs the stop codon of the uORF is recognized 
as a premature stop codon that triggers nonsense-mediated mRNA decay and 
leads to degradation of the transcript (Fig. 1.10d)186,187.  
 
 
Figure 1.10. Upstream open reading frames regulate translation. a. Upstream open reading frames (uORFs) 
are short open reading frames encoded upstream of the main open reading frame (mORF) on mRNA transcripts. 
Depicted here is a schematic overview of the organization of a mRNA containing an uORF. m7G: 7-
methylguanosine cap. The regulation of translation by uORFs occurs via different mechanisms: b. Ribosomes 
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recognize the translation initiation codon of the uORF, translate it and dissociate after termination, never reaching 
the mORF. c. The uORF encodes a functional peptide that upon translation stalls ribosome progression on the 
mRNA. d. The uORF translation triggers nonsense-mediated mRNA decay and the mRNA transcript is degraded 
before the mORF is translated. e. The 40S subunit skips the uORF translation initiation codon and initiates 
translation at the mORF f. The uORF is recognized by the ribosome and translated, but upon translation the 
ribosome does not dissociate completely from the mRNA. The 40S subunit remains attached, scans down to the 
mORF and initiates translation there. 
 
Nevertheless, uORFs do not always completely abolish translation of the mORF. The 
mORF is translated when the ribosomes scan across the uORF initiation codon (also 
called leaky scanning) (Fig. 1.10e)153. Moreover, the post-termination 40S subunit 
may remain associated with the mRNA after uORF translation and can resume 
scanning downwards to the start codon of the mORF (Fig. 1.10f)188,189. The efficiency 
of reinitiation is dependent on the length of the translated uORF, the distance of the 
uORF termination codon to the start codon of the mORF and also the physiological 
state of the cell188-191 (Fig. 1.11.). The shorter the translated uORF the more likely it is 
that downstream reinitiation will occur192,193. This is mainly due to the initiation factors 
not having dissociated completely by the time the uORF stop codon is reached. But 
also an increase in the distance between the uORF stop codon and the mORF start 
codon has been described to positively influence mORF translation190,194.  
 
Figure 1.11. Structural characteristics influencing the functionality of uORFs. A schematic depiction of the 
different parameters that influence the efficiency of uORF-mediated translation regulation is shown. UORFs are 
located in the 5’ leaders of mRNA transcripts between the 5’cap (7-meGpppG) and the main open reading frame 
(mORF). The regulatory potential of the uORF depends on several parameters: (i) the position within the 5’leader 
relative to the 5’cap and the start codon of the mORF, (ii) the length of the encoded ORF, (iii) the strength of the 
Kozak sequence around the uORF start codon (blue line) and (iv) the sequence surrounding the termination 
codon (orange line).    
 
In plants and yeast it was shown that additionally the intercistronic sequence affects 
the efficiency of reinitiation195,196. Single nucleotide exchanges in the intercistronic 
VSDFH EHWZHHQ WKH X25) DQG WKH &(%3Į 25) VWURQJO\ LQIOXHQFH WKH UHLQLWLDWLRQ UDWH 
of the scanning ribosomes197. The distance between the 5’ cap and the uORF start 
codon is also important. If the uORF start codon is too close to the 5’cap the 
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preinitiation complex will not have formed during the scanning process to initiate 
translation on the start codon of the uORF198. 
 
1.2.3. Viruses depend on the translation machinery of their host cell 
Viruses fully rely on the translation apparatus of the host cell. The protein synthesis 
machinery is used to produce the viral tools needed to hijack the cell, replicate the 
genome, generate progeny virions and in the case of herpesviruses, establish a 
persistent infection.  
EBV-derived mRNAs contain the conserved structural features of host cell 
transcripts: the 5’ 7-methylguanosine cap and the polyadenylated 3’ tail. Therefore, 
ribosome loading and translation occur in the same manner.  
The densely packed genome of EBV makes precise annotation of translated ORFs 
from genomic information alone particularly difficult. Generally, the large viral 
genomes of herpesviruses have been annotated by the usage of sequence homology 
to already described genes in other subfamilies and in silico predictions with defined 
ORF annotation parameters. This approach is useful at predicting canonical ORFs of 
defined sizes but does not include small ORFs or ORFs with alternative translation 
initiation sites. In recent years the development of a new approach to study 
translation in greater detail has lead to the discovery of small ORFs and alternative 
translation initiation in different virus families199-201. The method used to identify these 
new genes is discussed in the following section.   
 
1.2.4. Defining translatomes by ribosome profiling 
Recently, translation has been utilized to annotate complex viral genomes more 
precisely and to gain mechanistic insight into gene expression regulation199-201. Dr. 
Nick Ingolia together with Prof. Jonathan Weissman have developed an experimental 
system to analyse translated transcripts at a given time point in a cell at single 
nucleotide resolution202 (Fig. 1.12.). The method exploits the property of the ribosome 
to physically enclose the mRNA at the site it is currently translating. This enclosure 
protects this particular mRNA fragment from digestion by nucleases. These ribosome 
protected footprints (RPFs) can subsequently be converted into cDNA libraries for 
sequencing. Combined with total RNA sequencing it can deliver detailed insights into 
which mRNAs produced at any given time in a cell are actually also translated.  
Furthermore, by using drugs that block ribosome progression directly after initiation 
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the method can be used to map previously unidentified translation initation sites202. 
By applying this method to different cell types under different physiological conditions 
Ingolia et al. have identified a plentitude of alternative translation initiation sites 
(aTIS) and previously uncharacterized open reading frames203,204. The method has 
also contributed to the identification of novel ORFs in several different viruses and 
has helped to elucidate the complex and dynamic translational events employed by 
these viruses during the infection process199-201,205.  
 
 
Figure 1.12: An overview over the ribosome profiling method. Cells of interest are lysed and treated with 
RNase. The RNA that had been loaded with ribosomes at time of lysis is incompletely digested due to the bound 
ribosomes. These ribosome-protected mRNA fragments (RPFs) can be purified. They are then converted into a 
cDNA library for next generation sequencing (NGS). 
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2. Aim of my thesis 
EBV is a widespread human pathogen that can cause cancers of lymphoid and 
epithelial origin. Fifty years have passed since the initial discovery of EBV and 30 
years since the sequencing of the B95-8 EBV strain. The development of next 
generation sequencing approaches has lead to a deeper understanding of genetic 
polymorphisms found in different virus isolates and has increased our understanding 
of the complex transcriptional processes that take place in infected cells during lytic 
replication. However, it is unclear whether the protein-coding potential of this 
complex DNA virus is completely understood. This is, in part, due to the complex 
transcriptional landscape observed in these cells but also due to the complex 
translational processes employed by mammalian cells.   
The aim of my thesis was to define the translation products of EBV-infected cells in 
the two EBV strains M81 and B95-8. The specific questions I addressed were:  
(i) What are the differences between the two strains?  
(ii) Do annotated open reading frames initiate at the sites annotated in data 
bases? 
(iii) Are there translated open reading frames that have not been recognized 
yet? 
(iv) Are the transcripts identified as non-coding truly non-coding? 
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3. Results 
 
3.1. Ribosome profiling of EBV-infected cells  
In order to map the full scope of translated ORFs in established LCLs, ribosome 
profiling libraries were generated of B cells transformed with either the B95-8 or the 
M81 EBV strain. The two different EBV strains were chosen for analysis as they differ 
substantially in their in vitro and in vivo characteristics1. In in vitro cultures of M81-
infected LCLs a small percentage of cells initiates spontaneous lytic replication. The 
B95-8 strain on the other hand is largely latent in cell culture. Therefore, an additional 
harringtonine-treated library was generated from HEK293 producer cell lines of B95-
8 that had been induced into lytic replication by transfecting a BZLF1-encoding 
plasmid.   
Ribosome profiling is based on the sequencing of 28-30 nucleotide (nt)-sized RNA 
fragments from nuclease-treated cell lysates. These fragments are protected from 
nuclease digestion by bound ribosomes and are called ribosome protected fragments 
(RPF). These RPFs are converted into a cDNA library and are subjected to next 
generation sequencing (NGS) (see Materials and Methods for the complete library 
preparation procedure).  
Each sample was treated either with cycloheximide alone or with harringtonine and 
cycloheximide together (Fig. 3.1). Both drugs are translation inhibitiors. 
Cycloheximide is a translation elongation inhibitor that interacts with actively 
translating ribosomes and stabilizes them on mRNA2,3. The cycloheximide-treated 
samples were used to obtain insight into the mRNAs actively translated in the 
infected cells. Harringtonine, on the other hand, is an antibiotic that specifically 
interacts with the 60S ribosomal subunit prior to 80S ribosome assembly and 
selectively arrests these on translation initiation sites4. The harringtonine-treated 
libraries were used to map annotated and novel translation initiation sites. 
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Figure 3.1: Schematic overview over the library generation procedure. M81 and B95-8-infected LCLs were 
treated with harringtonine (Harr) or cycloheximide (CHX) and lysed. The lysates were then loaded onto linear 
sucrose gradients and ultracentrifuged to separate mRNAs according to their ribosome loading. The gradients 
were then fractioned with a gradient fractionator and for harringtonine-treated lysates the fractions containing 
mRNAs loaded with one ribosome were collected (highlighted in grey on the left). For cycloheximide-treated 
lysates the fractions containing polysomal mRNAs were collected (highlighted in grey on the right). These 
fractions were then treated with RNase I to digest mRNA segments not covered by ribosomes. The remaining 
ribosome-protected fragments were then purified and converted into a cDNA library for next generation 
sequencing (NGS). The sequenced fragments were then aligned to the human and viral genomes.  
 
Sucrose density gradient ultracentrifugation was used to seperate polysomes from 
monosomes, ribosomal subunits and free RNAs (Fig. 3.1 and 3.2.a). Subsequent 
fractionation of the gradients enabled isolation of different ribosomal populations with 
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their associated mRNAs. During fractionation, the continuous UV absorbance profile 
of the single fractions was recorded at 254 nm. 
For the cycloheximide-treated samples, the polyribosomal fractions were collected for 
library generation (Fig. 3.1). Treatment with harringtonine caused a shift in the 
distribution of ribosome-bound mRNAs. The polyribosomal fraction was depleted and 
a strong peak was observed in the 80S monosome-containing fraction (Fig. 3.1). This 
was due to the selective inhibition of initiating ribosomes. This fraction was then 
collected for library preparation. A summary of the sequencing reads obtained from 
each library can be viewed in Appendix I.  
The lytic replication level of LCLs was determined in parallel on the days of profiling 
by immunofluorescence staining for the lytic cycle proteins BZLF1 and gp350. The 
quantification of cells positive for these proteins is given in Fig. 3.2b. BZLF1 is an 
immediate early lytic protein required to initiate lytic replication in cells. It is a marker 
for the early stages of lytic replication. The gp350 glycoprotein is the viral entry 
receptor and is expressed during the late stages of lytic replication.  
 
 
 
 
Figure 3.2: Polysome profile of LCLs and lytic replication levels in the different strains. a. The individual 
fractions from a polysome profile of B95-8-infected LCLs were collected, the RNA was purified and an agarose 
gel was run to visualize the 18S and 28S ribosomal RNAs present in the different fractions. Fractions 8 and 9 
contain non-ribosome associated RNAs and small RNA species. Fraction 10 contains mainly the 40S ribosomal 
subunit. Fraction 11 contains mainly the 60S ribosomal subunit. Fractions 12 and 13 contain the translation-
competent 80S ribosome and all subsequent fractions contain increasing numbers of translating 80S ribosomes. 
b. Lytic replication levels of infected cells used for ribosome profiling were determined on the day of sucrose 
density ultracentrifugation by immunofluorescence stainings for the lytic cycle proteins BZLF1 and gp350. The 
quantification of these stainings is shown as a bar plot. Quantifications of both replicates are summarized here. 
Error bars show the standard deviation between the two replicates. 
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As with conventional transcriptome data, abundance is measured during the 
sequencing reaction. The different reads are counted based on the number of times 
that particular sequence is read5. The different libraries contained varying amounts of 
reads that could be mapped to the viral genome (Appendix I). It ranged from 0.01 to 
1% of total mapped reads. This is in line with Arvey et al. who reported that on 
average they could map 0.1 to 1% of total RNA sequencing-derived reads to the EBV 
genome6.  
The reads derived from ribosome profiling range in size from 25 to 32 nucleotides. 
Ideally the majority of reads is in the size range of 27 to 30 nucleotides. This was the 
case for most of the LCL-derived libraries (Fig. 3.3 and Appendix II).  
 
 
Figure 3.3: Fragment length distribution of ribosome footprints. Representative fragment length distribution 
plots of sequenced ribosome-protected fragments are shown a. The length distribution of reads from the 
cycloheximide-treated library generated from M81-infected LCLs is shown  b. The length distribution of reads from 
the 5 min harringtonine-treated library generated from M81-infected LCLs is shown. For fragment length 
distribution plots of all libraries generated see Appendix II.  
 
Following sequencing and mapping, the reads aligning to the cellular genome were 
used to compile metagene analyses of the data sets. This was done to further assess 
the quality of the generated libraries (Fig. 3.4). These revealed an increase in read 
density past the start codon in the cycloheximide-treated samples (Fig. 3.4a) and an 
accumulation of reads surrounding start codons upon harringtonine treatment (Fig. 
3.4b). 
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Figure 3.4: Metagene analysis. Relative RPF densities surrounding the start and stop codons of annotated and 
highly expressed coding cellular genes in representative libraries derived from M81-infected LCLs are shown a. A 
representative plot of relative read densities in the cycloheximide-treated library is shown. b. A representative plot 
of relative read densities in the harringtonine-treated library is shown.  
 
The reads that aligned to the viral genome were sorted according to different 
categories of the viral gene locus (Fig. 3.5). The viral reads sequenced in the 
cycloheximide-treated libraries to a large proportion were mapped to the two EBV-
encoded small RNAs (EBERs) (Fig. 3.5a). Between these two RNAs, EBER1 shows 
significantly higher coverage. Previous studies have shown that EBER1 is bound by 
the ribosomal protein L22 which is part of the 60S subunit7. The proportion of reads 
mapping to the EBER RNAs decreased in the harringtonine-treated libraries (Fig. 
3.5b). This might be due to competitive interaction of harringtonine with the 60S 
subunit4.  
A significantly smaller proportion of reads mapped to protein-coding genes (AUG 
start codon and coding DNA sequence (CDS)). In M81-infected LCLs, more reads 
aligned to coding regions of the transcriptome than in the B95-8-infected cells (Fig. 
3.5a). The classification of the reads highlights the selective accumulation of 
ribosomes on translation initiation sites upon harringtonine treatment in the reads that 
aligned with the cellular and viral genes (Fig. 3.5b). Additionally, an increased 
fraction of reads mapped to the 5’leaders of transcripts in these libraries.  
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Figure 3.5: Read classification in the different ribosome profiling libraries. a. The stacked bar graphs show 
the classification of reads mapping to known viral genes from cycloheximide-treated libraries. Reads that 
intersected several classification features were sorted with following preference: AUG (start codon), CDS (coding 
DNA sequence), 5’leader, 3’untranslated region (3’UTR), non-coding RNA, intron, intergenic. The EBER RNAs 
were grouped into their own class due to their high abundance. b. Classification of reads obtained from the 
harringtonine-treated libraries as in a. 
 
 
3.2. Differences in host gene translation between B95-8 and M81-
infected LCLs 
From the RPFs that were successfully aligned to the human genome, the read 
densities were calculated and expressed as reads per kilobase of coding DNA 
sequence normalized by the median over all transcripts. This quantification was used 
to infer differential translation between the two strains. A core analysis using the 
Ingenuity Pathway Analysis (IPA) software from Quiagen was performed. Only the 
cycloheximide-treated samples were used here. The top scoring canonical pathways 
and their representation in the two strains are shown in Fig. 3.6. IPA used the 
Fisher’s exact test to assign significance through p-value calculation. Most of the top 
scoring pathways were more strongly enriched in the B95-8-infected samples. It is 
difficult to assess whether these differences truly stem from the differences between 
the two strains or whether this is due to the general broader expression of genes in 
B95-8 infected LCLs (Fig. 3.6a). Interestingly, the eIF2-signaling-associated pathway 
was more significantly enriched in the M81-infected samples. This pathway is directly 
linked to translation.  
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Figure 3.6: Ingenuity Pathway Analysis (IPA) of canonical pathways found to be most significantly 
enriched in genes covered by ribosome protected fragments (RPFs). a. Venn diagram summarizing the 
number of differentially translated genes between the two strains. The overlapping region between the two circles 
highlighted in blue indicates genes that were translated in both strains. b. The top canonical pathways that 
showed enrichment in genes covered by RPFs as determined by IPA analysis are shown. The heat map was 
generated by comparison of the cycloheximide-treated libraries from both strains. The p-value was calculated 
using Fisher’s exact test by the IPA software. The significance of the results is given as –log of the p-value.  
 
 
A further functional analysis of the RPF-associated genes in the studied LCLs 
identified biological functions particulary represented in these cells. These included 
organismal injury and morphology and cancer-associated pathways (Fig. 3.7). Again, 
functions associated with translation such as protein synthesis and post-translational 
modifications ranked higher in M81-infected LCLs than in cells infected with B95-8.  
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Figure 3.7: Diseases and biological functions associated with translated transcirpts in M81 and B95-8-
infected LCLs. The top 20 relevant pathways associated with different diseases and biological functions as 
determined by IPA are shown. The functions are sorted according to significance as determined by the p-value 
starting from the top with most significant to least signifcant. The –log p value is plotted as calculated by Fisher’s 
exact test. A p-value of 0.05 was used as threshold for significance. a. Pathway ranking for M81-infected LCLs. b. 
Pathway ranking for B95-8-infected LCLs. 
 
 
3.3. Viral mRNA translation in B95.8 and M81-infected LCLs 
Following the functional analysis of host cell translation and the general classification 
of virus-derived RPFs, the individual EBV ORFs were analysed for ribosome 
coverage. A global overview over the read coverage for the cycloheximide-treated 
samples of the M81- and B95-8-infected LCLs is shown in Fig. 3.8. The M81-infected 
LCLs show almost complete coverage of the viral genome (Fig. 3.8a). The extent of 
bidirectional coverage over the whole EBV genome is lower in B95-8-infected LCLs 
and is mostly restricted to annotated viral genes (Fig. 3.8b).  
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Figure 3.8: M81-infected LCLs show evidence for global bidirectional translation of the viral genome. a. 
Global overview over the M81 genome with coverage tracks of the cycloheximide-treated library seperated 
according to strand direction of the mapped RPFs. The green track shows reads that are oriented in the rightward 
direction (defined as the forward (fwd) strand) and the red track shows reads that are oriented in the leftward 
direction (defined as the reverse (rev) strand). Below the tracks the gene annotation of the viral genome is shown. 
b. The B95-8 cycloheximide-treated library is shown with parameters as in a. 
 
For detailed analysis of the individual ORFs the genes were classified according to 
the viral life cycle phase they were primarily associated with: (i) latent and (ii) lytic 
genes.  
In the cycloheximide-treated libraries, the reads were additionally classified according 
to their localization within the respective mRNA transcript. Two categories were 
distinguished: reads that mapped within the 5’leader of the transcripts and reads that 
mapped within the protein-coding region (coding DNA sequence (CDS)). The 
cycloheximide-derived data was utilized to calculate the ratios between ribosome-
protected footprints outside (within the 5’leader) versus inside a respective ORF 
(out:in ratio) (Fig. 3.9a). The method is derived from Chew et al.8. High ratio values 
indicated enrichment of footprints within the candidate ORF while low ratio values 
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meant a stronger accumulation of footprints within the 5’leaders of the analysed 
mRNA transcripts. 
The harringtonine-derived data was used to calculate the ratios between footprints 
mapped to the 5’leader versus the footprints mapped to the annotated start codon 
(Fig. 3.9b). This ratio was indicative of the ribosome’s efficiency to reach the start 
codon of the candidate gene.  
 
 
Figure 3.9: Data evaluation in the two library types. a. Ribosome footprints derived from cycloheximide-treated 
samples were used to calculate out:in ratios by dividing the number of normalized footprints mapped within the 
5’leader of the mRNA transcript (out) by the number of reads mapped to the ORF (in). The nucleotide length of 
the respective feature was used to normalize the values. b. Ribosome footprints derived from harringtonine-
treated libraries were used to calculate 5’leader:AUG ratios. Here the reads mapping to the 5’leader of a 
candidate gene were divided by the reads mapping to the annotated start codon (AUG) of the respective gene. 
 
 
3.3.1. Latent genes  
First, the ribosome coverage of EBV’s latent genes was analysed. Seven of the ten 
latent genes encoded by EBV are expressed from one genomic region, termed the 
EBNA transcription unit (Fig. 3.10a). They are transcribed from one of two promoters, 
the C promoter (Cp) or W promoter (Wp). All seven genes exhibit unusually long 
5’leaders. The other three genes (LMP1, LMP2A, LMP2B) are located close to or, in 
the case of the LMP2s, span the terminal repeats. LMP2A and LMP2B are protein 
isoforms steming from the same genomic region. This makes definitive assignments 
of RPFs to either gene impossible and therefore these two proteins are summarized 
here as LMP2. 
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Figure 3.10: Ribosome coverage on latent transcripts. a. Overview over the EBNA transcription unit. The unit 
is under the control of two promoters (Cp and Wp). The expression of six EBNA genes and latent BHRF1 is 
directed from these two promoters. *EBNA-LP transcription is simplified in this figure and only the longest EBNA-
LP isoform is shown. b. The read distribution on latent genes in the cycloheximide-treated samples is shown. 
Reads were classified according to their localization on mRNA transcripts: coding DNA sequence (CDS) and 
5’leader of the mRNA transcript (5’leader). Left: Reads derived from M81-infected LCLs are plotted. Right: Reads 
derived from B95-8-infected LCLs are plotted. LMP2A and LMP2B transcripts are summarized as LMP2. EBNA-
LP was omitted due to the repetitive nature of its exons and the difficulties of unambiguous mapping associated 
with it. The reads mapping to the 5’leader region shared by all Cp-derived genes were divided by seven (EBNA-
LP, EBNA2, BHRF1, EBNA3A-C, EBNA1) and a proportion of these reads was ascribed to the total reads in the 
5’leaders of each gene. Furthermore, the reads mapping to the U exon, which is shared by the EBNA3 family of 
genes and EBNA1, were divided by four and ascribed to the respective 5’leaders. For each gene the longest 
mRNA isoform was considered in the analysis. 
 
 
The latent genes generally have an overall lower coverage in M81-infected LCLs 
compared to B95-8 (Fig. 3.10b). However, the overall pattern of latent protein 
translation is comparable between the two strains with EBNA2 and LMP1 being the 
two genes with the highest ribosomes coverage (Fig. 3.10). All latent genes show 
ribosome coverage within their 5’leaders in both strains. The out:in ratios of EBNA1, 
EBNA3A and EBNA3B were almost identical between the two strains (Fig. 3.11a). 
LMP1 had a higher out:in ratio in M81 compared to B95-8. This is also reflected in 
the 5’leader:AUG ratios indicating that more ribosomes accumulate in the LMP1 
5’leader in M81 (Fig. 3.11b). 
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Figure 3.11: Ribosome coverage on latent transcripts. a. The ratios between reads mapping to the 5’leader 
vs. the reads mapping to the remaining open reading frame of the respective genes are shown. Cycloheximide-
treated libraries were used for ratio calculation. b. Ratios of reads derived from the 5’leaders of the latent genes to 
the reads covering the annotated start codon are shown. Harringtonine-treated libraries were used for ratio 
calculation.  
 
 
3.3.2. Lytic genes  
In the M81-infected LCLs, all lytic genes annotated in the NCBI EBV genome 
annotation were found to be associated with ribosomes (Fig. 3.12). The extent of 
their association with the cellular translation machinery varied but because no 
transcriptome analysis was performed here, no assertion over the differential 
translation efficiency can be made.  
Even though the B95-8 EBV strain has been described to be predominantly latent in 
vitro, several lytic cycle genes were found to associate with the cellular translation 
machinery (Fig.3.13). Some of these genes showed ribosome association rates that 
were comparable to those found in the M81-derived samples (Fig. 3.13). 
Furthermore, the BNLF2a gene exhibited stronger ribosome coverage in B95-8-
infected LCLs than in M81. Though initially identified as a lytic cycle gene, BNLF2a 
has recently been detected at the mRNA level in latently infected cells9. The 
ribosome profiling data further supports this observation and indicates that not only is 
this gene transcribed during latency but it is also translated.  
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Figure 3.12: Lytic transcripts associate with ribosomes at varying degrees. a. The graph shows lytic genes 
sorted according to their association with ribosomes in M81-infected LCLs. The ribosome coverage of 
cycloheximide-treated samples is shown. The ORFs of the BdRF1 and BVRF2 genes overlap substantially as do 
the genes of BLLF1 and BLLF2. Therefore, these four genes could not be included in the analysis of the 
cycloheximide-treated samples as unambiguous assignment of reads to these genes is not possible. b. Read 
coverage of the lytic cycle genes BHLF1 and LF3 are shown separately due to their high abundance in lytically 
replicating cells. Below the ORF coverage of the latent genes is shown.  
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Finally, the BMRF1 gene was chosen to further validate the data obtained from 
ribosome profiling of B95-8-infected LCLs. Not only did this gene show clear 
ribosome footprints within its ORF in the cycloheximide-treated samples, but it also 
exhibited a very prominent peak on its start codon in the harringtonine-treated 
libraries (Fig. 3.14a). In order to confirm the presence of BMRF1 mRNA within B95-8-
infected LCLs, a real-time qantitative PCR (RT-qPCR) analysis was performed on 
three independent LCLs established with the B95-8 strain. As a positive control, 
LCLs established from the same blood samples with the M81 strain were used. The 
negative controls were matcKHG /&/V HVWDEOLVKHG ZLWK WKH 0 ¨=5 RU WKH %-8 
¨%05) YLUXVHV 7KH 0 ¨=5 YLUXV LV D PXWDQW GHULYHG IURP WKH 0 VWUDLQ +HUH 
the lytic cycle transactivators BZLF1 and BRLF1 are deleted and LCLs infected with 
this virus cannot initiate lytic replication. On the other hand the B95- ¨%05) YLUXV 
is a B95-8-derived mutant devoid of the BMRF1 gene. BMRF1 RNA was detected in 
B95-8-infected LCLs, albeit at approximately half the level found in M81-infected 
LCLs (Fig. 3.14b). Interestingly, BMRF1 RNA was also detected at low levels in M81 
¨=5-infected LCLs even though the main transactivators of this gene: BZLF1 and 
BRLF1 were deleted in this strain. This indicates that BMRF1 on the one hand can 
be transcribed independently of BZLF1 and BRLF1 but also that it might be 
transcribed during latency at low levels as well.   
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Figure 3.13: Comparison of ribosome coverage on lytic genes in B95-8 and M81-infected LCLs. a. The 
graph bar shows the ribosome coverage of lytic cycle genes in LCLs established with the B95-8 (positive values) 
or M81 strain (negative values). Depicted is the data from the cycloheximide-treated libraries. CDS: coding DNA 
sequence. The genes are grouped according to their temporal expression during reactivation: IE: immediate early 
genes. E: early genes. L: late genes.  
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The low levels of BMRF1 transcript in RT-qPCR analysis indicated that most 
probably only a low number of cells would express the protein. The protein product of 
BMRF1 was additionally analysed by immunofluorescence staining. This allowed us 
to specifically look at single cells in the culture and potentially identify BMRF1 
expressing cells. Indeed, BMRF1 positive cells were identified in B95-8-infected cells 
albeit at a 40-fold lower level than in M81-infected LCLs (Fig. 3.14c).  
These experiments confirmed that the ribosome coverage on lytic genes in B95-8 did 
not stem from artifacts or contaminations with M81 samples introduced during library 
preparation. Furthermore, they confirmed that the latency III gene expression 
program of B95-8-transformed is not strict but that a small number of cells can and 
do enter lytic replication.  
 
 
Figure 3.14: BMRF1 is expressed in B95-8-infected LCLs. a. Ribosome profiles around the BMRF1 gene in 
B95-8-infected LCLs. Top panel: cycloheximide-treated samples (CHX), lower panel: harringtonine-treated 
samples (Harr). b. The dot plot shows RT-qPCR measurements for BMRF1 transcript abundance in three 
independent LCLs generated with the viral strains indicated below. M81: positive control, lytically replicating 
strain. B95- SUHGRPLQDQWO\ ODWHQW VWUDLQ 0 ¨=5 0-derived mutant deleted in the BZLF1 (Z) and BRLF1 (R) 
genes and therefore incapable of lytic replication. B95- ¨%05) %-8-derived mutant deleted in the BMRF1 
gene. Results are plotted relative to the expression level of M81-infected LCLs. c. Immunofluorescence staining 
for BMRF1 protein expression and quantification of positive cells. The dot plot shows the quantification for 5 
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independent LCLs established with the B95-8 or M81 strain. A representative image of a cell infected with the 
B95-8 strain expressing BMRF1 is shown below.  
 
 
3.4. Ribosomes associate with non-coding RNAs 
Next we analysed the ribosome association of viral non-coding RNAs. As already 
mentioned before, the EBERs show extensive association with the cellular translation 
apparatus (Fig. 3.5). The secondary structures of the EBER transcripts are shown in 
Fig. 3.1510. The majority of reads that align to EBER1 in all ribosome profiling 
libraries can be mapped to a region adopting stem-loop structures but not described 
to bind any cellular protein (Fig. 3.15a, highlighted in orange). For the EBER2 
transcripts different regions of the transcripts are protected from RNase I digestion 
depending on which ribosome profiling library is analysed (Fig. 3.15b). In the 
cycloheximide-treated samples, the dominant peak observed in the libraries is at the 
5’end of the transcript (Fig. 3.15b). It encompasses a part of the reported La antigen 
binding site. In harringtonine-treated samples the major peak is observed at the 
3’end of the transcripts. This also encompasses part of the reported La antigen 
binding site but also includes a longer region of the transcript that is part of the stem-
loop structure of EBER2.  
We also see mapping of reads to viral and cellular small non-coding RNAs such as 
microRNAs and small nucleolar RNAs (data not shown). These observed peaks most 
likely do not reflect true translation but rather these transcripts are protected from 
nuclease digestion through their association with other RNA binding proteins such as 
the RNA-induced silencing complex into which miRNAs are assembled.  
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Figure 3.15: The EBER1 and EBER2 secondary structures reproduced from Iwakiri 201611. Schematic 
depictions of the EBER secondary structures are shown. The blue rectangles highlight EBER RNA structures 
previously shown to interact with cellular proteins. Highlighted in orange are the regions where the majority of 
reads aligning to the EBER transcripts map to. For EBER2 the left orange region is the dominant peak in the 
cycloheximide-treated libraries while the highlighted sequence on the right side of the stemloop structure is the 
predominant peak in the harringtonine-treated libraries (shown here for M81).  
 
 
The BHLF1 gene which has recently been proposed to encode a long non-coding 
RNA contained high numbers of ribosome footprints12 (Fig. 3.16a). The same was 
the case for its positional equivalent at the second oriLyt LF3 (data not shown). Most 
of the reads mapped to the 5’leaders of these transcripts (Fig. 3.16b). These genes 
consist of highly repetitive sequences in their putative coding region which makes the 
unambiguous mapping of reads in this region impossible. This was taken into 
account by quantifying the reads mapping within the tandem repeats just once. The 
ribosome association was observed in both strains for BHLF1 although the M81-
derived samples exhibited significantly higher coverage (Fig. 3.16b/c). BHLF1 was 
initially described as a lytic gene and was only later discovered to also be expressed 
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in latent cells from a distinct latent promoter13-16. In the cycloheximide-treated B95-8-
derived libraries, a significant proportion of reads mapped to the 5’leader of BHLF1 
while in M81 a significant amount of reads were also identified within the ORF (Fig. 
3.16b/c). This was also true for the LF3 gene in M81. The LF3 gene is deleted in the 
B95-8 genome.  
 
 
Figure 3.16: BHLF1 and LF3 transcripts show extensive association with ribosomes. a. Ribosome footprints 
mapping to the BHLF1 gene from M81-infected LCLs are shown. Both libraries are represented: cycloheximide-
treated samples (CHX) and harringtonine-treated samples (Harr). The annotated translation initiation codon is 
depicted. The arrowhead indicates the direction of translation of the gene. b. Read distribution on the different 
segments of the BHLF1 and LF3 genes from the cycloheximide-treated M81-infected LCL samples. c. Read 
distribution on the different segments of the BHLF1 and LF3 genes from the cycloheximide-treated B95-8-infected 
LCL samples. d. The ratios between reads mapping to the 5’leader vs. the reads mapping to the remaining open 
reading frame of the respective genes are shown. Cycloheximide-treated libraries were used for ratio calculation.  
e. Ratios of reads derived from the 5’leaders of the latent genes to the reads covering the annotated start codon 
are shown. Harringtonine-treated libraries were used for ratio calculation. 
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The out:in ratios were high in both strains for BHLF1 (Fig. 3.16d). The same was true 
for LF3 in the M81-derived library. This further highlighted the strong accumulation of 
reads within the 5’leader of the transcripts, rather than in the protein-coding regions. 
On the other hand, the 5’leader:AUG ratio was comparable to the EBNA3 family of 
proteins (Fig. 3.11b) which are known to generate protein product. When analysing 
the distribution of BHLF1 transcripts within the polysomal fractions of M81-infected 
LCL lysates, the mRNA was found to preferentially localize to the lighter polysomal 
fractions devoid of translating ribosomes (Fig. 3.17).  
 
 
Figure 3.17: BHLF1 RNA preferentially sediments in the lighter polysomal fractions. a. Quantification of 
BHLF1 transcripts determined by RT-qPCR within the different fractions of a polysome profile. M81-infected LCLs 
were used for fractionation and two independent LCLs are shown. The signal intensity is given relative to the 
signals measured in fraction 8. The GAPDH gene was used for normalization of the measured Ct values.  
 
 
3.5. Putative EBV proteins are associated with ribosomes 
The ribosome profiling approach further enabled the analysis of putative EBV 
proteins where the definitive presence of a protein product remains to be 
demonstrated. These transcripts are derived from the EBV BART locus (Fig. 3.18a). 
This locus encodes a family of highly alternatively spliced and polyadenylated 
transcripts. The first four BART introns of this locus are processed into miRNAs. The 
leftward directed transcripts (RPMS1, RPMS1A and A73) have been subject of 
debate for a long time. Recombinant protein is produced in in vitro experiments but 
none of the putative protein products have been detected in natural infection17,18.  
The rightward directed LF1 gene has so far only been identified on the RNA level 
from RNA sequencing experiments during lytic replication of induced Akata cells. For 
LF2, the function of the protein has been established and is included here as 
reference for a protein-coding transcript expressed from this locus19-21.  
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The LF2 gene shows the strongest ribosome coverage in its coding region among 
these four genes (Fig. 3.18b). It also shows the lowest out:in ratio (Fig. 3.18c). The 
5’leader:AUG ratio is also low (Fig. 3.18d). This indicates that the LF2 transcripts 
have more ribosomes within the coding ORF than in the 5’leader. In comparison, the 
LF1 gene shows high ribosome coverage within its 5’leader in the cycloheximide-
treated samples (Fig. 3.18b). This leads to a high out:in ratio (Fig. 3.18c). Interstingly, 
this changes in the harringtonine-treated samples. Here, the 5’leader:AUG ratios are 
the lowest among the BART locus-derived genes (Fig. 3.18d). A closer analysis of 
the harringtonine-treated samples also shows a clear accumulation of reads on its 
start codon (data not shown), indicating that this gene might be translated.   
 
Figure 3.18: Ribosome profiling of BART transcripts. a. A schematic overview over the EBV BART region with 
the encoded genes is shown. The deletion in the B95-8 strain is indicated. Arrowheads indicate transcription 
direction of the genes. Image is not to scale. b. Read counts and distribution within the annotated ORFs of 
transcripts derived from EBV’s BART locus. Only the results of M81-infected LCLs are shown as a large part of 
this locus is deleted in B95-8. c. Out:in ratios calculated from cycloheximide-treated samples. d. Ratios of reads 
mapping to the 5’leader versus the annotated AUG start codon of the respective genes are plotted. Harringtonine-
treated samples were used for calculation of the ratios.  
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Figure 3.19: Ribosome coverage of poorly characterized EBV transcripts. Read distribution of poorly 
characterized EBV lytic transcripts. Data is derived from cycloheximide-treated libraries. BLLF2 was not included 
in the analysis due to extensive overlap with the BLLF1 gene. Only coding DNA sequence (CDS) coverage is 
shown as the 5’leaders of BXRF1 and BNLF2b overlap with other viral coding genes.  
 
 
Furthermore, three EBV putative proteins, so far only described at the RNA level and 
with unknown functions, were also analysed (Fig. 3.19). All three genes are 
described as lytic genes and are known to be induced upon lytic reactivation but are 
detected in both strains in the ribosome profiling libraries. Of these three genes, 
BNLF2b shows strongest ribosome coverage in both strains. The other two genes 
are present at significantly lower levels. Interestingly, while BXRF1 and BTRF1 show 
higher coverage in M81-derived libraries as would be expected for lytic cycle genes, 
the BNLF2b gene shows a 3-fold higher per nucleotide ribosome coverage in B95-8. 
To assess the relevance of this observation, RT-qPCR measurements were 
performed for BNLF2a and BNLF2b transcripts in LCLs transformed by either of the 
two viruses (Fig. 3.20). BNLF2a is a lytic gene involved in immune evasion and has 
recently been reported to be expressed also in latently infected cells9. Indeed, both 
genes were detected in B95-8-infected LCLs at signficantly lower levels than in M81 
(Fig. 3.20). However, the ribosome profiling data indicates that BNLF2b is more 
efficiently translated in the B95-8 strain.  
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Figure 3.20: BNLF2 mRNA transcripts are expressed in B95-8-transformed LCLs. a. RT-qPCR analysis for 
BNLF2a transcripts in total RNA purified from M81- and B95-8-transformed LCLs. Results are plotted relative to 
the expression level of M81-infected LCLs. b. RT-qPCR analysis for BNLF2b transcripts in total RNA purified from 
M81- and B95-8-transformed LCLs. Results are plotted relative to the expression level of M81-infected LCLs. 
 
 
3.6. Ribosome coverage of newly identified EBV-derived polyA+ 
RNA transcripts 
Several recently published mRNA sequencing experiments of EBV-infected LCLs 
induced into lytic replication by B cell receptor crosslinking have identified about 300 
novel virus-derived transcripts22-24. In these studies, the EBNA2 and EBNA3 family of 
proteins have been found to give rise to antisense transcripts. Of these, the protein 
encoded by the mRNA antisense to the encoded EBNA3C transcript has also been 
detected in independent mass spectometry experiments25.   
The cycloheximide-treated samples, derived from the cells transformed by the 
lytically replicating strain M81, show extensive ribosome coverage antisense to the 
EBNA3C gene (Fig. 3.21a). This is not observed in the B95-8-transformed LCLs (Fig. 
3.21b). On the other hand, the harringtonine-treated samples do not indicate 
translation initation at the predicted ORF start24 (data not shown). Antisense 
ribosome coverage is also observed for EBNA3A and EBNA3B in M81-infected LCLs 
(data not shown). However, all EBNA3 transcripts show RPFs located upstream and 
downstream of the putative antisense-ORFs as well, indicating that further proteins 
are encoded here.  
There is no significant ribosome coverage of the antisense EBNA2 transcripts in M81 
(Fig 3.22a). This is in line with O’Grady et al.’s prediction that the EBNA2 antisense 
transcript is most likely non-coding24.  
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Figure 3.21: Antisense-EBNA3C shows ribosome coverage in the lytically replicating strain M81. a. 
Overview over the EBNA3C genomic region in the M81 strain. The grey track shows the combined reads 
mapping to this region. Below: The coverage tracks of the cycloheximide-treated library are seperated according 
to strand direction of the mapped RPFs. The green track shows reads that are oriented in the rightward direction 
(defined as the forward (fwd) strand) and the red track shows reads that are oriented in the leftward direction 
(defined as the reverse (rev) strand). b. The B95-8 cycloheximide-treated library is shown with parameters as in a.  
 
 
Many of the novel genes described by O’Grady et al. are alternatively spliced 
isoforms of previously annotated EBV genes24. Due to the short fragment size of 
RPFs the ribosome profiling data cannot distinguish between the different protein 
isoforms of these genes.  
Even though the cycloheximide-treated library of M81 shows extensive bidirectional 
ribosome coverage almost over the entire EBV genome (Fig. 3.8) the harringtonine-
treated libraries do not show translation initiation sites that are present in all 
biological replicates.  
Furthermore, EBNA1 has previously been described to encode an alternate protein 
within its ORF in a nested open reading frame26,27. Here also, the ribosome profiling 
data could not confirm the translation of this ORF (data not shown).   
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Figure 3.22: Antisense-EBNA2 is not significantly associated with ribosomes in M81. a. Overview over the 
EBNA2 genomic region in the M81 strain. The grey track shows the combined reads mapping to this region. 
Below: The coverage tracks of the cycloheximide-treated library are seperated according to strand direction of the 
mapped RPFs. The green track shows reads that are oriented in the rightward direction (defined as the forward 
(fwd) strand) and the red track shows reads that are oriented in the leftward direction (defined as the reverse (rev) 
strand). b. The B95-8 cycloheximide-treated library is shown with parameters as in a. 
 
 
3.7. Novel small open reading frames are encoded in the EBV 
genome 
Further analysis of the harringtonine-treated libraries lead to the identification of 28 
novel small open reading frames. Three of these were classified as small open 
reading frames (Table 1). The 25 remaining small ORFs were classified as upstream 
open reading frames as they were found to be encoded within 5’leaders of viral 
genes (Table 2).  
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Moreover, previously described uORFs of several human genes could be confirmed 
in the data set (see Appendix III). UORFs are short open reading frames localized in 
the 5’leaders of mRNA transcripts preceding the main ORF (mORF). They are 
thought to mainly function as repressors of downstream translation although in some 
cases uORFs have been shown to mediate reinitiation of translation at the 
downstream encoded mORF28,29.  
Ribosome profiling identified several of these regulatory elements in the EBV 
genome using the harringtonine-derived data set. Not all identified uORFs were 
present in both strains. An overview over their localization within the EBV genome in 
the different strains is given in Fig. 3.23 and their characteristics are summarized in 
Table 2.  
 
 
Figure 3.23: EBV encodes upstream open reading frames. A schematic depiction of the distribution of novel 
small open reading frames across the EBV genome in the different samples. Figure is not to scale.  
 
 
All latent genes were found to encode at least one uORF in their 5’leader and several 
of the lytic genes were also found to utilize this type of gene expression regulation. 
The majority of the uORFs do not contain AUG as an initiation codon and among the 
non-canonical initiation codons CUG predominates (Table 2).  
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In order to further determine the relevance of the identified uORFs the sequence 
conservation level was determined by comparing the sequences of the uORFs 
identified by ribosome profiling with 122 sequenced EBV strains published at the time 
of analysis (Fig 3.24a). The LMP1 uORF conservation level is shown as an example 
in Fig. 3.24b. The sequenced strains exhibiting polymorphisms are listed below the 
consensus sequence. Apart from the BHLF1 uORFs the strongest sequence 
deviation from the consensus sequence was observed in the LMP1 uORF. The 
conservation level of the uORFs is generally high, indicating functional relevance.  
 
 
! &'!
 
Figure 3.24.: Conservation level of putative uORFs. a. Summary of the uORF conservation analysis is shown. 
Conservation levels of the uORF start codon (first column) and of the uORF reading frame (second column) were 
considered seperately. b. The alignment shows the sequence polymorphisms of the LMP1 uORF between 
different EBV strains. Only strains showing polymorphisms are shown here. Black dots indicate conserved 
nucleotides, light grey dashes indicate nucleotide deletions. Highlighted in red is the uORF start codon.  
 
 
3.7.1. Genes encoded in the EBNA transcription unit are regulated by several 
uORFs 
The EBNA transcripts comprise 7 genes that are all transcribed from the same two 
promoters during latency III (Fig 3.25). Except for the EBNA-LP protein, all genes 
from this transcription unit share a common 5’leader sequence generated from 
splicing of the W repeat region that also makes up the EBNA-LP open reading 
frame13,30. Following the splicing of the W1 and W2 exons, splicing to the unique Y1 
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and Y2 exons takes place, followed by splicing to the unique BHRF1 or EBNA genes. 
The BHRF1 protein is a viral bcl-2 homologue with anti-apoptotic activity just like its 
cellular counterpart31. It was primarily described as a lytic gene transcribed from its 
own promoter32. Later analyses identified its expression also in latent cells sharing a 
common 5’leader with the EBNA genes33. Several uORFs identified in the ribosome 
profiling data are encoded within the 5’leader of these genes (Fig. 3.25). When 
analysing the uORF characteristics we also took a closer look at the Kozak 
consensus sequences surrounding the start codons of the uORFs (Fig. 3.26). 
 
 
Figure 3.25: The EBNA transcription unit and the localization of the newly identfied uORFs. Depicted is an 
overview over the EBNA transcription unit. The EBNA transcripts which encompass EBNA-LP, EBNA2, EBNA3A-
C and EBNA1 as well as the latent form of BHRF1 are expressed from two promoters: Cp and Wp. *EBNA-LP 
transcription is simplified in this figure and only the longest EBNA-LP isoform is shown. 
 
 
We found that all four of the identified short uORFs in the Cp-initiated EBNA 
transcripts are embedded within a weak Kozak sequence. Even though their 
ribosome coverage is quite pronounced in our data, it is unlikely that they will have a 
profound inhibitory effect on the translation of the downstream encoded EBNA genes 
because of their close proximity to the 5’ cap and the distance to the start codons of 
the respective main ORFs (Fig. 3.25). The most likely gene these elements could 
actively regulate are the Cp-initiated EBNA-LP transcripts as the relative distance 
between the uORFs’ termination codons to the mORF’s start codon is the shortest. 
Interestingly, the Cp-initiated EBNA-LP start codon is surrounded by a strong Kozak 
sequence indicative of efficient translation initiation (GAGCaugGC) while the Wp-
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initiated EBNA-LP transcripts that are not regulated by a long 5’leader sequence 
containing uORFs is surrounded by a intermediate Kozak sequence (ACAAaugGG).  
 
 
Figure 3.26: Kozak consensus sequence strength of the identified viral uORFs. Summarized is the strength 
of the Kozak consensus sequence surrounding the uORF start codons. 
 
 
The Y2 uORF is surrounded by a strong Kozak sequence and it is in closer proximity 
to the start codons of genes it might regulate. The shortness of the uORF, which is 
only 7 amino acids long indicates that it may not completely abolish translation of the 
downstream encoded mORFs. The Kozak consensus sequences of the downstream 
encoded genes range from strong (EBNA3C) to weak (EBNA1). The distance 
between the Y2uORF termination codon and the start codon of the BHRF1 gene is 
short and indicates a strong regulatory function of the uORF for this protein. The 
BHRF1 ORF is present on several different mRNA isoforms. The latent BHRF1 ORF-
containing transcripts are initiated from the Cp and Wp. The lytic BHRF1 transcripts 
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initiate from a more proximal lytic promoter. This endows the ORF with a different 
5’leader sequence that harbours two alternate uORFs where one of them can further 
give rise to two different peptide products depending on the splicing of the BHRF1 
5’leader. To complicate things further, BHRF1 has recently been described to be 
produced from a further mRNA isoform expressed during lytic reactivation24. This 
transcript is produced from alternative splicing of W1-W1 exons instead of the 
conventional W1-W2 repeat exon splicing which endows the BHRF1 transcript with a 
shorter 5’leader.  
 
 
Figure 3.27: The Y2 exon encodes a 7 amino acid long uORF. a.Upper panel: A schematic overview over the 
Cp-and Wp-initiated EBNA-LP protein is shown with the W1 and W2 repeat exons depicted as grey rectangles. 
Highlighted in red is the Y2 exon which harbours the stop codon of the EBNA-LP reading frame and the Y2uORF 
in a shifted reading frame. Middle panel: The close-up figure shows the Y2 exon with the AUG start codon of the 
Y2uORF highlighted in red. The read coverage in representative M81-transformed ribosome profiling libraries is 
shown after cyclohexmide treatment alone or with harringtonine. Lower panel: A close-up of view of the red 
rectangle from the middle panel is shown displaying the ribosome coverage in detail for the Y2uORF. The 
nucleotide sequence of the uORF is boxed in black with the start codon highlighted in red. b. Representative 
ribosome coverage from the B95-8-transformed LCLs (upper panel) and HEK293-2089 cells (lower panel). RPF 
coverage is shown for harringtonine (Harr)-treated samples.  
 
! '+!
In addition to the short uORFs close to the 5’cap of the Cp-initiated EBNA transcripts 
and the downstream spliced Y2uORF, the EBNA1 and EBNA3 family mRNA 
transcripts further encompass the U exon further downstream in the EBV genome. 
This exon harbours an additional uORF that is placed upstream of the start codons of 
these respective genes. This UuORF is surrounded by a strong Kozak sequence and 
is similarly short as the Y2uORF (6 aa). It is further localizad within an IRES 
sequence reported to direct EBNA1 translation34 (Fig. 3.25 and 3.28). An IRES is a 
cis-acting RNA structure and offers the cell an alternative to cap-dependent 
translation initation especially during stress conditions35. A complex RNA secondary 
structure is formed that can directly bind the 40S subunit of the ribosome.  
 
 
Figure 3.28: The U exon encodes an uORF within an IRES element. The nucleotide sequence of the U exon 
from the M81 strain is shown. The IRES consensus sequences identified by Isaksson et al.34 are indicated in bold 
and underlined letters. The start codon of the uORF is highlighted in red.  
 
 
3.7.2. Viral protein translation is regulated by upstream open reading frames 
To verify that the small ORFs identified in the 5’leaders of several viral genes were 
indeed uORFs and that these did exert a regulatory role on the downstream encoded 
main ORF, six of the uORFs were studied in reporter assays. The 5’leader 
sequences were synthesized by Eurofins Genomics and were recloned upstream of 
of the Firefly luciferase (FLuc) gene for reporter activity measurements (Fig. 3.29a). 
The Y2uORF was chosen as it showed strong ribosome accumulation in the M81 
strain (Fig. 3.27a) and in the B95-8-derived libraries (Fig. 3.27b). The intergenic 
sequence between the uORF and the EBNA2 gene in the M81 virus background was 
cloned between the Y2uORF and the luciferase start codon.  
The complete U exon comprising the UuORF and IRES sequence were cloned into 
the FLuc vector.  
LMP1 contained a weak uORF that is very close to the annotated start codon (2 nt 
between uORF stop and LMP1 start). The LMP1 start codon of M81 is surrounded by 
a very strong Kozak sequence but nevertheless a distinct peak accumulates at the 
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start codon of the uORF in the harringtonine treated libraries. On the other hand, the 
5’UTR of the B95-8 LMP1 gene contained the same uORF but less reads were 
visible in the harringtonine treated libraries on its start codon. Here, the majority of 
reads accumulated on the annotated start codon of LMP1. B95.8 contained 106x  
more reads on the LMP1 start codon compared to the uORF while in the M81 strain, 
there were only 2.1x more reads on the LMP1 start compared to the uORF (data not 
shown).  
The BFLF2 ORF is, according to our analyses, regulated by two uORFs. Both uORF 
stop codons end close to the BFLF2 start codon. We chose to mutate the more 
proximal uORF here.  
The BORF2 uORF is also surrounded by a strong Kozak sequence and exhibits 
close proximity to the translation start site of the mORF.  
BKRF3 encodes two uORFs that extend beyond the start codon of the gene. A 
5’leader was synthesized that had both uORFs deleted.  
The different luciferase constructs were transfected into HEK293 cells alongside a 
Renilla luciferase (RLuc) encoding transfection control vector and luciferase activity 
measurements were performed 24h following transfection. Deletion of the Y2uORF 
start codon in the luciferase constructs lead to an approximately 2-fold increase in 
signal intensity arguing for a repressive function of this uORF (Fig. 3.29b). The 
UuORF with the IRES element included did not show any difference in luciferase 
assays. The deletion of the LMP1 uORF lead to a 1.5-fold increase in luciferase 
expression. The deletion of the BFLF2 uORF was comparable to the Y2uORF 
deletion with a 2-fold increase in FLuc expression. The uORFs of the other two lytic 
genes studied did not show an increase in FLuc expression upon deletion.  
These results confirm that the identified uORFs, at least in part, act to repress the 
downstream encoded mORF.  
 
 
Figure 3.29: Mutational analysis of viral uORFs in dual luciferase reporter assays. a. Schematic depiction of 
the Firefly luciferase (FLuc) reporter constructs with different viral 5’leaders containing uORFs cloned upstream of 
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the luciferase gene. b. FLuc activity measurements normalized to co-transfected Renilla Luciferase (RLuc). Error 
bars show the standard deviation of at least six independent transfections. The paired-end t-test was used to 
calculate the p-value. Asterisks summarize the p-value: ****< 0.0001. ns: not significant. 
 
 
3.8. Alternative translation initiation 
As already highlighted above, ribosome profiling in the presence of harringtonine is a 
powerful tool to map translation initation sites on a given transcript2. Apart from the 
identification of small ORFs and regulatory uORFs in the viral genome the underlying 
data set also enabled the identification of alternative translation initation sites (aTIS) 
within annotated viral genes (Table 3). The majority of identified aTISs were N-
terminal truncations of annotated viral proteins. Typically they were initiated at non-
canonical (non-AUG) start codons. This has been described to occur preferentially in 
these situations36,37. 
 
 
 
As an example, the BKRF3 gene is shown in Fig. 3.30.  The ORF is preceded by two 
uORFs in its 5’leader that extend beyond the start codon of BKRF3. This has 
previously been described to promote the expression of N-terminally truncated 
protein isoforms38-40. This might also be the case for BKRF3 where pronounced 
translation initiation at two downstream CUG codons can be observed. However, in 
the luciferase assays described in the previous section no increase in FLuc activity 
was detected upon deletion of the two uORFs.  
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Figure 3.30: The BKRF3 ORF is regulated by two uORFs and contains two internal alternative translation 
initiation sites. The schematic arrangement of the genomic region around BKRF3 is shown with the two uORFs 
starting in the BKRF3 5’leader highlighted in red. The two alternative translation initiation sites are indicated. The 
panel below shows the ribosome coverage of this region in the cycloheximide-treated library (CHX). The panel 
below that shows the ribosome coverage of this region from the 5 min harringtonine-treated library (Harr).  
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4. Discussion 
This is the first study that analyses global translational processes in EBV-infected 
cells. This analysis on the nucleotide level has identified novel small open reading 
frames and alternative translation initation sites. Moreover, the study is based on the 
physical association of ribosomes and thereby provides experimental data to identify 
these ribosome-associated regions rather than relying on in silico prediction 
methods.  
The computational scoring of translated ORFs and initiation sites described so far 
perform badly when analysing ORFs with low ribosome coverage1-5. The percentage 
of viral transcripts detected in LCLs was low compared to the cellular transcriptome. 
This results in signficantly lower ribosome coverage of viral transcripts as well. This 
was particularly true for the majority of lytic transcripts analysed in the M81-
transformed LCLs as the percentage of lytically replicating cells was below 10%. 
Therefore, the computational analyses published for ribosome profiling data were not 
applicable in our case. As a consequence, manual screening of the viral genome was 
performed. Partial manual annotation of novel ORFs has also been done for strongly 
lytically replicating viruses such as human cytomegalovirus (HCMV) and Kaposi’s 
sarcoma herpesvirus (KSHV)5,6.  
A recent publication has shown that for the transcripts with low ribosome coverage, 
the translation inhibitor pateamine offers a more robust way of studying translation 
initiation sites by ribosome profiling compared to harringtonine7. This drug could be 
used as an alternative to harringtonine in future studies on EBV translation.  
 
4.1 Ribosome profiling reveals differences in translation of cellular genes in 
two different EBV strains 
B95-8-transformed LCLs showed a broader expression of cellular genes. This could 
be due to the host shut-off mechanism of lytically replicating cells mediated by the 
lytic cycle protein BGLF5 in M81-infected cells8. However, only 3-6% of M81-infected 
LCLs are positive for BZLF1 during lytic replication in vitro, making it unlikely that this 
small percentage of replicating cells would influence cellular protein translation so 
profoundly in the total library. Another cause could be the slower cell cycling kinetics 
observed in M81-infected LCLs compared to B95-8 (data not shown). B95-8-infected 
LCLs are also metabolically more active (data more shown). These two attributes of 
B95-8 could lead to a broader gene expression profile compared to M81. 
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Interestingly, genes that were associated with translation were more strongly 
represented in the M81-derived libraries. This leads to the assumption that translation 
is more directly influenced by EBV in the M81 strain. For example, the lytic cycle 
protein SM has been reported to alter translation and preferentially stimulate 
translation of its target genes9.  
 
4.2 Ribosome profiling allows for the analysis of annotated viral proteins and 
the identification of novel viral genes 
The global bidirectional association with ribosomes of almost the entire EBV genome 
in M81-infected LCLs is in line with O’Grady et al.’s report of global bidrectional 
transcription in lytically replicating cells10,11. The transcripts they have identified in 
their transcriptome studies seem to be translated to a large part as well. This is at 
least observed in the cycloheximide-treated samples. The harringtonine data did not 
confirm any translation initation on the newly identified transcripts that were 
consistent between biological replicates. The ribosome profiling data confirmed that 
antisense-transcripts generated from the EBNA3 family of genes are extensively 
associated with ribosomes in the M81-infected LCLs. Yet again, harringtonine data 
could not confirm initiation at the presumed start codons. The EBNA3A and EBNA3B 
antisense genes have been predicted by O’Grady et al. to be nuclear which they 
have also demonstrated by fluorescence in situ hybridization analysis10. The 
ribosome profiling data here suggests that these genes are actually translated. At the 
same time the global bidirectional ribosome coverage was selective, as was shown 
for the antisense EBNA2 gene. Here, both strains showed hardly any ribosome 
coverage supporting the claim that this region is not translated10.  
Previous publications have used machine learning approaches to identify novel 
protein-coding genes using ribosome profiling4. Again, due to the low coverage of 
viral genes this approach is not reliable for this data set and it cannot be excluded 
that genes have been overlooked during the manual screening of the viral genome.   
For future studies on translation of the newly identified genes, an EBV strain should 
be used that exhibits higher lytic replication levels. Unfortunately, EBV strains that 
spontaneously replicate in vitro are rare and M81 is a strain with the highest lytic 
replication levels observed in cell culture so far. An alternative would be to use a 
strain that can be induced into lytic replication to high levels, such as the Akata strain 
used by O’Grady et al.10. It is a more artificial system to study lytic replication but 
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would lead to a higher ribosome coverage of viral genes and allow for a more precise 
annotation of translated transcripts.  
Surprisingly, the B95-8-infected LCLs showed evidence for the translation of several 
lytic cycle proteins even though the strain is known to be in latency III in vitro. BMRF1 
expression in a few cells further showed that the proteins that were shown to be 
associated with ribosomes in the ribosome profiling experiments were actually 
translated and yielded protein product. BMRF1 is an early lytic gene and functions as 
the viral DNA polymerase processivity factor12-14. Its transcription is induced by 
BZLF1 and BRLF115. The detection of BMRF1 RNA in RT-qPCR experiments with 
0 ¨=5-infected LCLs argues for an additional BZLF1 and BRLF1-independent 
expression of this gene.  
BMRF1 has also been reported to act as a transcriptional regulator that enhances 
BALF2 promoter activity as well as activates BHLF1 transcription12-14,16,17. Therefore, 
it is not unlikely that the protein is also expressed independently of its transactivator 
BZLF1.  
 
4.3 Ribosomes associate with non-coding RNAs 
The peaks observed on small non-coding RNAs most likely stem from protection of 
this RNA species from RNase digestion by associated proteins, such as the RNA-
induced silencing complex. Interestingly, the peaks observed in the different libraries 
shift depending on which inhibitor is used. This is said to be indicative of true 
translation. Intriguingly, Lauressergues et al. have described that miRNA precursors 
in plants encode short peptides that regulate subsequent miRNA processing18. 
Further validation is needed to determine whether the observed peaks are signs of 
true translation and whether EBV, and by extension mammalian cells, utilize this 
mechanism to regulate miRNA processing.  
BHLF1 and LF3 show a high number of ribosome footprints. This is, on the one hand, 
in agreement with the previously reported high transcription level of these genes 
upon induction of lytic replication19-21. On the other hand, no definitive protein product 
has been detected in EBV-infected LCLs so far22-24.  
The 5’leader of BHLF1 accumulates many RPFs which in part can be ascribed to the 
presence of three uORFs. Furthermore, the BHLF1 RNA is very GC-rich25 and RNA 
hairpins form in GC-rich sequences that are inhibitory to translation. This is especially 
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the case when the GC-rich region is localized close to the 5’cap as is the case for 
BHLF126,27.  
BHLF1 resembles the HCMV Beta2.7 RNA. This is a long RNA transcript that is 
generated from a repeat region within the HCMV genome similar to BHLF125,28. The 
Beta2.7 RNA transcript has sparked similar debate over its coding capacity. On the 
one hand, a putative ORF was identified in a laboratory strain of HCMV29. However, 
sequencing of additional strains showed that this region was disrupted in four isolates 
analysed in a separate study, arguing against a peptide-dependent role of this 
gene30. The putative ORF of BHLF1 is also not present in all EBV strains31.  
Recently, the association of the HCMV Beta2.7 RNA with ribosomes was 
demonstrated by ribosome profiling5. Here, the RNA was predicted to encode several 
small ORFs. In a follow-up study, the group demonstrated that T cell responses 
against some of the small ORFs presumed to be translated from this long RNA 
transcript could be detected in the serum of HCMV+ individuals3. However, earlier 
reports have demonstrated the inhibitory effect of the 5’leader sequence of the 
Beta2.7 RNA on its own translation29,32. Interestingly, one study reported the 
inhibitory effect to be mediated by the complex structure of the 5’leader29 while the 
other identified two uORFs that mediated the translational repression32. Taking all 
these studies into consideration, it seems that the Beta2.7 RNA of HCMV does not 
encode an essential protein, but that the transcript is associated with the host cell 
translation machinery and can be translated under certain conditions. The same 
might hold true for BHLF1.  
Recent studies have categorized BHLF1 as a viral long non-coding RNA (lncRNA). 
Rennekamp et al. have shown that the deletion of the transcription start site of 
BHLF1 leads to a drop in lytic replication levels in these cells while the mere silencing 
of the start codon of the putative BHLF1 ORF does not show any effect25. This is 
supported by the polysome profiling experiments performed in my work. The BHLF1 
mRNA was preferentially localized in the lighter fractions of the sucrose gradient. 
This argues that BHLF1 is not translated in LCLs. As a lncRNA, BHLF1 is 
hypothesized to function in cis at the OriLyt by interacting with the DNA and forming 
a stable RNA-DNA helix also termed R-loop. This generates a local single-stranded 
DNA region that is utilized for lytic replication initiation25.  
Previous studies on cellular lncRNAs have suggested their association with 
ribosomes confers a cellular mechanism to regulate their stability, subcellular 
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localization and degradation by triggering nonsense-mediated mRNA decay (NMD)33-
35. NMD is frequently triggered by uORFs of which BHLF1 has three36,37. 
Furthermore, Mendell et al. have shown that the knockout of the Rent1 protein which 
is essential for NMD function, leads to upregulation of specific mRNA transcripts that 
contain uORFs38. Additionally, Smith et al. have shown that inhibition of NMD in cells 
increases the expression level of some lncRNAs that have been shown to be 
associated with ribosomes, arguing for the utilization of translation as a degradation 
signal for this RNA class39. The BHLF1 protein product has been detected in LCLs 
chemically induced into lytic replication22,23. Interestingly, the Western blots in both 
publications exhibit a ladder of protein products indicating extensive degradation of 
the protein. This suggests that if the BHLF1 transcript is indeed translated under 
certain settings, then the protein is highly unstable.  
LF3 closely resembles BHLF1 and it is believed that the two genes have arisen out of 
gene duplication40. It is the positional homologue of BHLF1 at the second OriLyt. For 
LF3 also, no consistent protein product was observed in Western blot but rather a 
protein ladder41.  
 
4.4 Putative EBV proteins are associated with ribosomes 
The LF1 and LF2 open reading frames have been described early on42. Using the 
Akata EBV strain, LF2 was identified as an early lytic gene of EBV43. It has since 
been shown to fulfil different roles in the infected cell with different protein 
interactions being involved, such as the viral BRLF1 protein or the cellular IRF744-47. 
LF1 shows some homology to LF2 and both genes are thought to have arisen from 
gene duplication of the viral BLLF3 gene48. LF1 transcripts have been detected in 
different sequencing data and the gene is listed as a lytic gene. When expressed as 
a GST-fusion protein in vitro, it was identified as binding to SUMO residues49.  
As is common to many EBV lytic genes, LF1 has a short 5’leader sequence. 
Nevertheless, in the cycloheximide-treated library, many reads are localized to the 
5’leader and only a low number of ribosomes are detected within the ORF. In the 
harringtonine-treated samples, this changes as is indicated in the low 5’leader:AUG 
ratio. The ratio is lower than for the translated LF2 gene. The cause for this drastic 
rearrangement of ribosomes upon harringtonine treatment is unknown. It could be 
that the LF1 ORF is not translated very efficiently and that this is reflected by the high 
number of reads detected in its 5’leader.    
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The BART-derived transcripts are another group of genes that have sparked debate 
over their translational status. BART transcripts are generated from a distinct 
genomic region in the viral genome and are characterized by extensive alternative 
splicing50,51. In my analysis, only A73 and RPMS1 were included because these 
transcripts can be distinguished from one another. The BART transcripts have been 
shown to exhibit a predominantly though not exclusive nuclear localization52.  
It is impossible to make assumptions about the translational state of these transcripts 
based on the ribosome profiling data alone. The coverage of these transcripts in all 
libraries is amongst the lowest of all viral genes. BART transcripts are not highly 
expressed in LCLs. On the other hand, BART transcripts have been reported to be 
expressed at very high levels in epithelial cells. A more precise statement over the 
translational status of these transcripts could perhaps be obtained from profiling of 
EBV-infected epithelial cells.  
Additionally, BART miRNAs are encoded and processed from these transcripts53. 
Due to a correlation between BART RNA expression and BART miRNA levels, it is 
believed that the BART transcripts are generated in order to produce the BART 
miRNAs rather than the putative proteins53,54. The ribosome association of these 
transcripts could be explained with the same argument as for the lncRNAs: the 
association allows for the removal of these transcripts via the NMD pathway after 
miRNA processing. Small nucleolar RNAs (snoRNAs), for example, are processed 
from longer RNA transcripts. After processing of the snoRNAs, the transcripts are 
translated and this triggers their degradation through NMD34. This allows the removal 
of the mature RNA after the biologically relevant snoRNAs have been excised from 
the introns of the message.  
 
4.5 The EBV genome encodes small and upstream open reading frames  
The ribosome profiling analysis of EBV-infected LCLs has identified three small open 
reading frames in the viral genome. ORFs are historically defined with a minimal 
length of 100 amino acids for functional protein generation55. Small ORFs were long 
ignored and thought to be by-products and non-functional. But there is rising 
evidence that they too encode functional proteins and several small peptides have 
been described that fulfil significant biological roles56-58. The same could hold true for 
the newly identifed viral small ORFs. Furthermore, previous ribosome profiling 
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studies on HCMV and KSHV have also identified small ORFs of unknown function in 
these viruses5.  
EBV depends on the cellular translation machinery to translate its mRNAs and thus is 
also susceptible to the cell’s regulatory networks. Translation enables almost 
immediate responses to extracellular and intracellular stimuli. Various regulatory 
elements function in cis on the affected mRNA. UORFs are such regulatory 
elements. Though described decades ago, these uORFs have in the last couple of 
years become widely appreciated as important fine-tuners of protein translation with 
relevance in several human diseases59-61. In human cells, 49-64% of genes are 
predicted to be controlled by at least one uORF62,63. They are especially clustered in 
oncogenes and transcription factors highlighting the importance for strict regulation of 
these genes64. Viruses are also known to use uORFs for the regulation of 
translation5,6,65.  
Generally, uORFs are associated with a reduction in translation level of the mORF62. 
However, depending on the physiological state of the cell they can also enhance the 
translation of the downstream encoded mORF66,67. 
The observation that all of the viral latent genes harbour at least one uORF within 
their 5’leaders suggests an important role for these small ORFs in the translational 
control of these genes. Furthermore, the start codons of the uORFs were conserved 
among all EBV strains studied. This further highlights their importance. Latent genes 
are critical factors for the transformation of the infected B cell but can also be 
cytotoxic to cells68. Therefore, latent gene expression needs to be tightly controlled. 
The strongest differences in ribosome coverage of latent genes were in LMP1 and 
EBNA2. Both genes have, through ribosome profiling analysis, turned out to be 
regulated by uORFs. The higher 5’leader:AUG ratio for LMP1 in the M81 strain 
indicates that the gene is more tightly regulated in this strain. The ribosome coverage 
of the uORF is higher in M81-infected cells and luciferase assays have further shown 
that this uORF exerts a repressive role on the downstream encoded ORF.  
The uORF-mediated regulation of EBNA2 is difficult to assess because the ribosome 
profiling data has shown that this gene is regulated by multiple uORFs. Additionally, 
EBNA2 shares its 5’leader sequence with other genes and it is impossible to 
determine how many of the RPFs detected in the 5’leader of this transcription unit 
are on transcripts that encode EBNA2. The Y2uORF which is one of the uORFs 
encoded upstream of the EBNA2 ORF has shown to have a repressive function in 
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luciferase reporter assays. However, not all cloned uORF sequences showed an 
effect on translation in the reporter assays. 
The deletion of the UuORF within the IRES sequence did not show any effect on the 
expression level of the luciferase ORF. This uORF is different in its composition 
compared to the other viral uORFs identified. It is encoded within an IRES element69. 
The lack of effect could be due to factors missing in the cells used for the reporter 
assays. That could be factors that are provided by the virus in natural infection. 
KSHV, for example, has been reported to control the expression of the vFLIP protein 
through an IRES. The IRES element is only functional in KSHV-infected but not in 
uninfected cells70,71. Furthermore, it could be that a cellular factor is missing to make 
the UuORF functional. Mehta et al. have shown that the mere presence of uORFs 
does not mean that the mORF will be repressed in translation72. They studied the 
mRNA of the Her-2 gene which contains an uORF in its 5’leader73 and showed that 
the uORF is non-functional in some cancer cells and that this overriding of uORF 
control is directed from a translational derepression element in the 3’UTR that can 
bind regulatory proteins72.  
The next question to ask concerning the UuORF is: why is it embedded within an 
IRES element? In fact, the combination of an uORF within an IRES has been 
described in mammalian cells74,75. The cat-1 gene, a stress-regulated arginine/lysine 
transporter, is translated through an IRES element that requires the translation of an 
uORF encoded within the IRES. Cellular stress leads to impairment of cap-
dependent translation. IRES elements and uORFs have been described to ensure 
the translation of critical genes during stress responses. For the cat-1 ORF, the 
translation of the uORF remodels the structure of the RNA and renders the IRES 
functional. This enables the subsequent translation of the cat-1 ORF74,75. Not only 
stress impairs cap-dependent translation. During mitosis, cap-dependent translation 
is also decreased. Here too, IRES-mediated translation is used to synthesize 
proteins critical for that cell cycle stage76-79.  
One of the genes that contain the UuORF/IRES in its 5’leader is EBNA1. EBNA1 is 
essential for the propagation of the viral genome during mitosis by tethering the viral 
genome to chromosomes. Therefore, its expression needs to be guaranteed also 
during mitosis and this might be facilitated by the uORF/IRES in the U exon.  
Furthermore, especially the uORFs encoded upstream of lytic genes might only be 
active during cellular stress. EBV has been reported to induce stress in cells through 
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expression of specific proteins80. Also, the lytic cycle induction is known to exert 
stress on the infected cell81. This might explain why not all of the uORFs of the lytic 
cycle genes studied in the reporter assays showed an effect upon deletion.  
The identified uORFs could also have a dual function depending on the physiological 
state of the cell. For example, Ebola virus uses an uORF to maintain the levels of L 
protein65. Under optimal conditions in the cell the uORF represses translation of the 
downstream-encoded L protein. When cells are stressed and translation is therefore 
globally downregulated the uORF manages to uphold expression of L protein.  
Another interesting aspect, is the biological relevance of the uORF-encoded 
peptides. Some of the identified uORFs showed strong conservation between EBV 
strains also within the coding region. UORFs have been reported to encode peptides 
that regulate the translation of the mORF. A well studied example is the uORF2 
encoded in the 5’leader of the gpUL4 gene of HCMV82,83. The function of this uORF 
depends on its amino acid sequence. The translated 12 aa long peptide remains 
associated with the ribosome at the termination codon as a peptidyl-tRNA complex.  
Furthermore, uORFs can balance the translation between two different proteins on 
bicistronic RNAs. The C0 ORF of hepatitis B virus prevents translation of the core 
protein and promotes reinitiation of translation at the polymerase gene further 
downstream84. The BKRF3 gene of EBV could be a good candidate for this type of 
uORF-mediated regulation. The BKRF3 gene encompasses alternative translation 
initiation and uORF-mediated regulation. According to the ribosome profiling data the 
5’leader of BKRF3 encodes two uORFs that extend past the start codon of the 
mORF. Additionally the protein is predicted to contain two alternative translation 
initation sites that start with CUG. BKRF3 is a DNA glycosylase protein85. During lytic 
replication the protein is localized in the nucleus in a complex including BALF5, 
BMRF1 and BRLF186. If BKRF3 is deleted viral DNA replication is defective. A 
catalytic mutant can restore DNA replication indicating that the enzymatic activity is 
not essential for this function. Interestingly, the alternative translation initiation sites 
identified within the BKRF3 ORF either start within or further downstream of the 
catalytic domain. This indicates that BKRF3 isoforms could be produced in EBV-
infected cells that lack enzymatic activity. The luciferase assays did not show an 
increase in activity upon deletion of these two uORFs. As mentioned in the previous 
section their functionality might depend on a factor of viral or cellular origin that was 
not present in the HEK293 cells used for the assays. 
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We find alternative translation initiation within several other viral genes as well. Most 
of these alternatively translated protein isoforms have a non-canonical start codon. 
Non-AUG alternative translation initiation was first discovered in viruses87,88. 
Alternative translation initiation has proven to be an important factor for the 
generation of protein isoforms and protein diversity in cells4,89. This leads to proteins 
differing in their N-terminal domains which in turn can alter their functions or change 
their subcellular localization90,91. For example, PTEN has been identified to encode a 
long version of the canonical protein that is termed PTEN-long. This protein is 
initiated 519 bp upstream of the annotated AUG from a CUG start site. This adds 173 
aa to the protein and makes it membrane-permeable. The long form is secreted and 
can enter into neighbouring cells thereby altering their behaviour90.  
One EBV N-terminal protein isoform has been described previously92. RAZ is 
transcribed from the same genomic locus as BZLF1. The N-terminal domain of RAZ 
is generated through a different transcription start site than BZLF1 and alternative 
splicing. This generates a protein that functions as an inhibitor of BZLF1.  
 
4.6 EBV infection remodels cellular gene expression processes 
EBV has been described to influence transcription in infected cells during lytic 
replication10. Multiple promoters are used to transcribe genes and extensive stop-
codon readthrough is observed that also influences cellular genes. To what extent 
EBV also alters translation in infected cells is unknown. Several EBV proteins have 
been described to exert direct or indirect effects on translation and the associated 
proteins. LMP1, for example, can trigger the unfolded protein response (UPR)93. This 
is a cellular stress response pathway. Furthermore, LMP1 has also been reported to 
FDXVH SKRVSKRU\ODWLRQ RI H,)Į94 %RWK 835 DQG H,)Į phosphorylation are known 
to act as global inhibitors of translation. In contrast, LMP1 has recently been 
described to increase eIF4E expression in NPC cell lines95. LMP2A has been 
reported to modulate PI3K/Akt signaling in cells which too has direct consequences 
for translation96. EBNA1 causes a redistribution of the ribosomal protein L4 from the 
cytoplasm to the nucleus97. The EBER transcripts redistribute the ribosomal protein 
L22 and sequester it away from polysomes98. Both L4 and L22 are components of 
the 60S ribosomal subunit. This is especially interesting when taking the hypothesis 
of “specialized ribosomes” into consideration41. The idea is that in mammalian cells, 
ribosomes are not all equal but as large molecular machines they can have unique 
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compositions that influence their activity. The heterogeneity in the ribosome can stem 
from the composition of the individual ribosome components ranging from variation in 
rRNA sequences to the association of different ribosome-associated factors. Post-
translational modifications can also lead to the generation of specialized ribosomes 
that have preferences for certain mRNAs.  
 
4.7 Future studies 
The underlying study has looked at translational profiles of EBV+ LCLs of two 
different strains. The relevance of the new insights gained from ribosome profiling still 
needs to be further defined and validated.  
Inclusion of uninfected primary B cells in ribosome profiling experiments is needed to 
further analyse the viral influence on translation. Furthermore, EBV is known to infect 
other cell types as well. Ribosome profiling experiments including infected epithelial 
cells could give us further insight into translation in another cell setting. It is already 
known that viral gene expression is different in different cell types. It would be 
interesting to know to what extent this applies to translation and the novel regulatory 
elements. Moreover, uORF-dependence has been shown to be highly dynamic in 
HCMV5. Translational profiling of lytically replicating cells at different timepoints after 
lytic cycle initiation would further our understanding into translation and translation-
mediated regulation of protein expression in EBV-infected cells.  
The approach of manual annotation of novel genes in combination with low lytic 
replication in the samples studied, most likely underestimates the novel ORFs 
identified. Arias et al. who have combined manual annotation with computational 
analysis have contributed to a 45% increase in KSHV genome annotation due to 
small peptide identification6. It is possible that LCLs with higher lytic replication levels 
will allow for even more small proteins to be identified in the EBV genome.  
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5. Materials 
 
5.1 Eukaryotic cell lines and culture medium  
HEK293 are human embryonic kidney cells generated by transformation with adenovirus1 
and were obtained from American Type Culture Collection (ATCC) (www.atcc.org) (ATCC: 
CRL-1573).  
HEK293 producer cell lines for the generation of virus stocks were generated from HEK293 
cells and have been described previously2,3. 
Primary B cells were isolated from anonymous human blood samples purchased from the 
blood bank of the University of Heidelberg. No consent from the ethics committee is required. 
The precise CD19+ B cell isolation protocol is described in the methods section.  
 
Culture medium for all cell lines was RPMI-1650 medium (Invitrogen) supplemented with 
10% fetal bovine serum (FBS) (Biochrom).  
 
5.2 Bacterial strains, culture medium and antibiotics  
'+Į This E.coli strain was used for routine cloning procedures and 
high copy number plasmid amplification. 
  
 
LB medium: 10g Tryptone (AppliChem), 5g Yeast extract (Sigma-Aldrich), 10g NaCl (Sigma-
Aldrich)in 1l H2O 
LB Agar: 32g LB-Agar (Invitrogen) supplemented with 5g NaCl (1% NaCl) 
 
Antibiotics used in this study 
Antibiotic company concentration 
ampicillin Serva 100 /ml 
 
 
5.3 Plasmids  
Vector plasmids 
pGL4.5[Fluc/CMV/Amp] Expression plasmid with the Firefly luciferase gene placed 
under the control of the strong HCMV promoter (ampicillin 
resistance) 
 
Expression and control plasmids  
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pCDNA3.1(+) Expression plasmid with a HCMV cloned in front of the multiple 
cloning site (Invitrogen) (ampicillin resistance) 
pGL4.5[Fluc/CMV/Amp] Expression plasmid with the Firefly luciferase gene placed 
under the control of the strong HCMV promoter (ampicillin 
resistance) 
pRL Expression plasmid with Renilla luciferase placed under the 
control of a strong SV40 promoter (ampicillin resistance) 
p509 Expression plasmid for BZLF1 under the HCMV promoter 
(ampicillin resistance) 
pRA Expression plasmid for gp110 under the HCMV promoter 
(ampicillin resistance) 
 
 
5.4 5’ transcript leader sequences (TLS) synthesized for reporter construct 
experiments 
 
# 
TLS sequence of 
viral gene 
Sequence (5’-3’) 
1423 LMP1 uORF 
AAGCTTGGCAGACCCCGCAAATCCCCCCGGGCCTCCATCCCCAGAAACAC
GCGTTGCTCTCTCGTAGGCGGCCTACATAAGCCTCTGTCACTGCTCTGTCA
GCTTCTTTCCTCAGTTGCCTTGCTCCTGCCACACTACCCTGACCATGGAAG
ATGCCAAAAACATTAAGAAGGGCCC 
1431 ¨LMP1 uORF 
AAGCTTGGCAGACCCCGCAAATCCCCCCGGGCCTCCATCCCCAGAAACAC
GCGTTGCTCTCTCGTAGGCGGCCTACATAAGCCTCTGTCACTGCTCCGTCA
GCTTCTTTCCTCAGTTGCCTTGCTCCTGCCACACTACCCTGACCATGGAAG
ATGCCAAAAACATTAAGAAGGGCCC 
1424 U uORF 
AAGCTTTGAGCCACCCACAGTAACCACCCAGCGCCAATCTGTCTACATAGA
AGAAGAGGAGGATGAAGACTAAGTCACAGGCTTAGCCAGGTAACTTAGGAA
GCGTTTCTTGAGCTTCCCTGGGATGAGCGTTTGGGAGAGCTGATTCTGCAG
CCCAGAGAGTAGTCTCAGGGCATCCTCTGGAGCCTGACCTGTGACCGTCG
CATCATAGACCGCCAGTAGACCTGGGAGCAGATTCACCGCCGCGGCCGTC
TCCTTTAAGACAAAATGGAAGATGCCAAAAACATTAAGAAGGGCCC 
1425 ¨U uORF 
AAGCTTTGAGCCACCCACAGTAACCACCCAGCGCCAATCTGTCTACATAGA
AGAAGAGGAGGATGAAGACTAAGTCACAGGCTTAGCCAGGTAACTTAGGAA
GCGTTTCTTGAGCTTCCCTGGGACGAGCGTTTGGGAGAGCTGATTCTGCA
GCCCAGAGAGTAGTCTCAGGGCATCCTCTGGAGCCTGACCTGTGACCGTC
GCATCATAGACCGCCAGTAGACCTGGGAGCAGATTCACCGCCGCGGCCGT
CTCCTTTAAGACAAAATGGAAGATGCCAAAAACATTAAGAAGGGCCC !
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1426 Y2 uORF 
AAGCTTCTCTTAGAGAGTGGCTGCTACGCATGAGAGCCAGCTTTGAGCCA
CCCACAGTAACCACCCAGCGCCAATCTGTCTACATAGAAGAAGAGGAGGA
TGAAGACTAAGTCACAGGCTTAGCCAGTTCCCTCTTAATTACATTTGTGCC
AGATCTTGTAGAGCAAGATGGAAGATGCCAAAAACATTAAGAAGGGCCC 
1427 ¨Y2 uORF 
AAGCTTCTCTTAGAGAGTGGCTGCTACGCATGAGAGCCAGCTTTGAGCCA
CCCACAGTAACCACCCAGCGCCAATCTGTCTACATAGAAGAAGAGGAGGA
CGAAGACTAAGTCACAGGCTTAGCCAGTTCCCTCTTAATTACATTTGTGCC
AGATCTTGTAGAGCAAGATGGAAGATGCCAAAAACATTAAGAAGGGCCC 
1432 BFLF2 uORF 
AAGCTTATTTAAATCCACACAAGTGGCCAGAGTGGGCAAAACAATCCTCGT
GGATGTCACTAAGGAACTGGACGTGGTCCTGCGCATCCACGGCCTTGAC
CTGGTACAGTCCTATCAAACTTCCCAGGTCTACGTGTGAAAAGTAAAACCG
ATGGAAGATGCCAAAAACATTAAGAAGGGCCC 
1433 ¨BFLF2 uORF  
AAGCTTATTTAAATCCACACAAGTGGCCAGAGTGGGCAAAACAATCCTCGT
GGACGTCACTAAGGAACTGGACGTGGTCCTGCGCATCCACGGCCTTGAC
CGGTACAGTCCTATCAAACTTCCCAGGTCTACGTGTGAAAAGTAAAACCG
ATGGAAGATGCCAAAAACATTAAGAAGGGCCC 
1434 BKRF3 TLS 
AAGCTTAGTCTGGCCTCCTTAAATTCACCTAAGAATGGGAGCAACCAGCT
GGTCATCAGCCGCTGCGCAAACGGACTCAACGTGGTCTCCTTCTTTATCT
CCATCCTGAAGCGAAGCAGCTCCGCCCTCACGAGCCATCTCCGTGAGTT
GTTAACCACCCTGGAGTCTCTTTACGGTTCATTCTCAGTGGAAGACCTGTT
TGGTGCCAACTTAAACAGATACGCATGGAAGATGCCAAAAACATTAAGAA
GGGCCC 
1435 ¨BKRF3 uORFs 
AAGCTTAGTCTGGCCTCCTTAAATTCACCTAAGAATGGGAGCAACCAGCT
GGTCATCAGCCGCTGCGCAAACGGACTCAACGTGGTCTCCTTCTTTATCT
CCATCCCGAAGCGAAGCAGCTCCGCCCTCACGAGCCATCTCCGTGAGTT
GTTAACCACCCCGGAGTCTCTTTACGGTTCATTCTCAGTGGAAGACCTGTT
TGGTGCCAACTTAAACAGATACGCATGGAAGATGCCAAAAACATTAAGAA
GGGCCC 
1436 BORF2 uORF 
AAGCTTACATATAGAGGAGCTAACCTTCGGGGCGGTTGCCTGTCTGGGGA
CATTTAGTGCTACTGACGGTTGGAGGAGGTCTGCCTTCAATTACCGTGGC
TCTAGCCTCCCCGTGGTGGAGATTGACAGCTTTTATTCCAACGTCTCTGAC
TGGGAGGTGATTCTCTAGACTTAACGGGAGGAAACAGGAGGAGGAGGGG
GACAAGAGCACAAAAGTGGTTCAGTGGACACCCACCACACAGCATGGAA
GATGCCAAAAACATTAAGAAGGGCCC 
1437 ¨BORF uORF  
AAGCTTACATATAGAGGAGCTAACCTTCGGGGCGGTTGCCTGTCTGGGGA
CATTTAGTGCTACTGACGGTTGGAGGAGGTCTGCCTTCAATTACCGTGGC
TCTAGCCTCCCCGTGGCGGAGATTGACAGCTTTTATTCCAACGTCTCTGA
CTGGGAGGTGATTCTCTAGACTTAACGGGAGGAAACAGGAGGAGGAGGG
GGACAAGAGCACAAAAGTGGTTCAGTGGACACCCACCACACAGCATGGA
AGATGCCAAAAACATTAAGAAGGGCCC 
 
Column 1 shows the plasmid number designated to the constructs after recloning into the 1272 Firefly luciferase 
expression plasmid. Column 2 lists the gene the uORF-containing 5’leader was derived from. Column 3 lists the 
sequences synthesized. The uORF sequence is highlighted in red, the mutation introduced to silence the uORF is 
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underlined in the mutant variant. The ATG of the luciferase gene is set in bold type. Each sequence is flanked by 
enzyme restriction sites (underlined sequences: 5’: HindIII and 3’: Bsp120I). TLS: transcript leader.  
 
 
5.5 Recombinant EBV clones  
Clone  name EBV strain  Description  
B240 M81 wt M81 recombinant M81 wild-type virus3 
B697 0 ¨=5 M81 
M81 with a deletion of the BZLF1 and 
BRLF1 gene  
2089 B95-8 wt B95-8 recombinant B95-8 wild-type virus2 
B072 B95- ¨%05) B95-8 
recombinant B95-8 with a deletion of 
the BMRF1 gene 
 
 
5.6 Oligonucleotides  
All oligonucleotides were synthesized by Eurofins Genomics.  
 
Oligos used for ribosome profiling 
Oligo function Sequence (5’-3’)  
Upper size marker 5’-AUGUACACGGAGUCGAGCUCAACCCGCAACGCGA-(Phos)-3’    
Lower size marker 5’-AUGUACACG  !"!#$!"$$$""$!$!"-(Phos)-3’ 
Reverse transcription 
primer  
5’-(Phos)-AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAG 
ATCTCGGTGGTCGC-(SpC18)-CAC TCA-(SpC18)-TTCAGACGTGT 
GCTCTTCCGATCTATTGATGGTGCCTACAG-3’ 
Biotinylated subtraction 
oligos* 
5’-GGGGGGATGCGTGCATTTATCAGATCA-3’  
5’-TTGGTGACTCTAGATAACCTCGGGCCGATCGCACG-3’  
5’-GAGCCGCCTGGATACCGCAGCTAGGAATAATGGAAT-3’  
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5’-TCGTGGGGGGCCCAAGTCCTTCTGATCGAGGCCC-3’ 
5’-GCACTCGCCGAATCCCGGGGCCGAGGGAGCGA-3’ 
5’-GGGGCCGGGCCGCCCCTCCCACGGCGCG-3’ 
5’-GGGGCCGGGCCACCCCTCCCACGGCGCG-3’ 
5’CCCAGTGCGCCCCGGGCGTCGTCGCGCCGTCGGGTCCCGGG-3’  
5’-TCCGCCGAGGGCGCACCACCGGCCCGTCTCGCC-3’ 
5’-AGGGGCTCTCGCTTCTGGCGCCAAGCGT-3’  
5’-GAGCCTCGGTTGGCCCCGGATAGCCGGGTCCCCGT-3’ 
5’-GAGCCTCGGTTGGCCTCGGATAGCCGGTCCCCCGC-3’ 
5’-TCGCTGCGATCTATTGAAAGTCAGCCCTCGACACA-3’ 
5’-TCCTCCCGGGGCTACGCCTGTCTGAGCGTCGCT-3’ 
forward library PCR 
primers 
5’-AATGATACGGCGACCACCGAGATCTACAC-3 %  
Indexed reverse 
primers (from 
NEBNEXT) 
Index #2:  
5 ғ-CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTT 
CAGACGTGTGCTCTTCCGATC-s-T-3 ғ 
 
Index #3:  
5 ғ- CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTC 
AGACGTGTGCTCTTCCGATC-s-T-3 ғ 
 
Index #4:  
5 ғ-CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTC 
AGACGTGTGCTCTTCCGATC-s-T-3 ғ 
 
Index #5:  
5 ғ-CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTC 
AGACGTGTGCTCTTCCGATC-s-T-3 ғ 
 
Index #6:  
5 ғ-CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTT 
CAGACGTGTGCTCTTCCGATC-s-T-3 ғ 
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Index #7:  
5 ғ- CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTT 
CAGACGTGTGCTCTTCCGATC-s-T-3 ғ 
*All biotinylated subtraction oligos were 5’ modified with a biotin-triethyleneglycol (TEG) tag.  
(Phos) indicates phosphorylation sites. (SpC18) indicates a hexa-ethyleneglycol spacer.  
-s- indicates a phosphorothioate bond 
 
Oligos used for Taqman qPCR* 
Oligo #  target gene  Sequence (5’-3’)  
54 EBV polymerase fwd 5’-AGTCCTTCTTGGCTAGTCTGTTGAC-3’ 
55 EBV polymerase rev 5’-CTTTGGCGCGGATCCTC-3’ 
96 EBV polymerase probe Fam-CATCAAGAAGCTGCTGGCGGCC-Tamra  
fwd: forward primer. rev: reverse primer. Fam: fluorescein amidite. Tamra: Tetramethylrhodamine Azide.  
*Human GAPDH was used as the endogenous control for the RT-qPCR experiments. The primer and probe mix 
for GAPDH was purchased ready-to-use from Applied Biosystems 
 
Oligos used for SYBR Green qPCR  
Oligo #  target gene  Sequence (5’-3’)  
1923 BMRF1 fwd 5’-CACCATGCTGGTGGTAGATG-3’ 
1924 BMRF1 rev 5’-GAGATGAGTCTGGGCATGGT-3’ 
2300 BHLF1 fwd 5’-ACCTACATGTCAACCGCCTC-3’ 
2301 BHLF1 rev 5’-GTGTATTGCTCTCGTTGCCA-3’ 
2559 BNLF2a fwd 5’-GTGCTTTGCTAGAGCAGCAGT-3’ 
2560 BNLF2a rev 5’-TTAGTCTGCTGACGTCTGGGT-3’ 
2561 BNLF2b fdw (B95-8) 5’-AGGACTGCATCCAACGCTT-3’ 
2562 BNLF2b rev (common) 5’-CCACACCATCCCAATTCA-3’ 
2563 BNLF2b (M81) 5’-AGGACTGCATCCAACGCTGC-3’ 
1609 GAPDH fwd 5’-CAATGACCCCTTCATTGACC-3’ 
1610 GAPDH rev 5’-TGGAAGATGGTGATGGGATT-3’ 
fwd: forward primer. rev: reverse primer.  
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Oligo used for sequencing of luciferase constructs 
Oligo # Sequence (5’-3’)  
1274 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
 
 
5.7 Chemicals & Reagents  
 
Chemicals & reagents company 
1-butanol AppliChem 
10 bp DNA ladder Invitrogen 
1kb DNA ladder Invitrogen 
1M Tris-HCl pH 8; RNase free Ambion 
20% SDS solution MP Biomedics 
3M sodium acetate pH 5.5, RNase-free Ambion 
Acetic Acid Sigma-Aldrich 
Agarose Sigma-Aldrich 
boric acid Sigma-Aldrich 
Bromphenol blue Serva 
CaCl2 Invitrogen 
Chloroform Carl Roth 
Complete Mini Protease Inhibitor Roche 
Cycloheximide Sigma-Aldrich 
D(+)Saccharose Roth 
DAPI Sigma-Aldrich 
DMSO Sigma-Aldrich 
dNTP mix Roche 
EDTA GERBU 
EDTA, RNase-free Invitrogen 
Ethanol Sigma-Aldrich 
Ethidiumbromide Carl Roth 
Fetal Bovine Serum Biochrom  
Ficoll Plus Amersham Biosciences 
Formaldehyde J.T. Baker 
Formamide Promega 
Glycerol VWR International 
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Glycine GERBU 
GlycoBlue Invitrogen 
Harringtonine LKT Laboratories 
Heat-inactivated goat serum Gibco 
Heparin sodium salt Sigma-Aldrich 
Hygromycin B Invitrogen 
Isopropanol Sigma-Aldrich 
KH2PO4 Carl Roth 
LB-Agar Invitrogen 
Metafectene Biontex 
Mini Protean TBE-Urea precast gels, 12 well, 
15% 
Bio-Rad 
MNCl2 Sigma-Aldrich 
MOPS Genaxxon 
MyOne streptavidin C1 DynaBeads  Invitrogen 
Na2HPO4 Sigma-Aldrich 
NP-40 Biochemika 
4% Paraformaldehyde (PFA) AppliChem 
PBS tablets for cell culture Gibco 
Phenol Carl Roth 
Potassium acetate (KAc) Carl Roth 
Random hexamers Invitrogen  
RbCl Acros Organics 
RNasin Promega 
RPMI-1640 (+)L-glutamine Gibco 
Sodium Acetate (NaAc) Carl Roth 
Sodium Chloride (NaCl) Sigma-Aldrich 
Sodium citrate Sigma-Aldrich 
sodium hydroxide (NaOH) AppliChem 
SYBR Gold Invitrogen 
TBE (10x), RNase-free Thermo Scientific  
Triton AppliChem 
TrizmaBase Sigma-Aldrich 
Trizol Ambion 
Trypan Blue Sigma-Aldrich 
Trypsin-EDTA (0.05%) Invitrogen 
Tryptone AppliChem 
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Tween 20 Sigma-Aldrich 
Water, PCR-grade, RNase-free Sigma-Aldrich 
Yeast extract Sigma-Aldrich 
 
5.8 Enzymes  
All restriction enzymes were purchased from Thermo Fisher Scientific.  
 
Other enzymes used in this study 
Enzyme company 
Alkaline phosphatase Roche 
AMV Reverse transcriptase Roche 
Dnase I Fermentas 
Phusion High-fidelity DNA polymerase ThermoScientific 
Proteinase K ThermoScientific 
RNase A Roche 
Rnase I Invitrogen 
SuperScript III Invitrogen 
SYBR Green Master Mix Applied Biosystems 
T4 DNA ligase Fermentas 
T4 PNK NEB 
T4 RNA ligase 2, truncated NEB 
Taqman Universal Master Mix Life technologies 
 
5.9 Antibodies  
 
Antibodies used for immunofluorescence stainings 
Name target Species Dilution company 
BZ.1 BZLF1 Mouse 1:300 Hybridoma supernatant 
72A1 gp350/220 Mouse 1:250 Hybridoma supernatant 
R3 BMRF1 mouse 1:1000 Merck Millipore 
Cy3 
Į-mouse IgG 
conjugated with Cy3 
Goat 1:300 
Jackson 
ImmunoResearch 
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5.10 Commercial kits 
 
Kit Company Application 
CircLigase Epicentre ribosome profiling 
DETACHaBEAD C19 Invitrogen Isolation of human primary B cells 
Dual Luciferase Reporter Assay System Promega Reporter assays 
Dynabeads CD19 Pan B Invitrogen  Isolation of human primary B cells 
Jetstar 2.0 Plasmid Midiprep Kit Genomed Preparation of plasmid DNA 
Universal miRNA cloning linker NEB ribosome profiling 
 
5.11 Buffers  
 
Buffer Formula 
Bind/wash buffer (2x)  
2M NaCl, 1mM EDTA, 5mM Tris (pH 7.5), 0.2% (v/v) 
Triton X-100 
Denaturing loading buffer (2x) 
98% (v/v) formamide, 10 mM EDTA, 300 µg/ml 
bromphenol blue 
DNA gel extraction buffer 300 mM NaCl, 10 mM Tris (pH 8), 1mM EDTA 
DNA loading buffer 
0.25% bromophenol blue, 40% (w/v) sucrose, 
dissolved in H2O 
Lysis buffer mini prep 1% SDS, 0.2M NaOH 
MOPS (10x) 0.2M MOPS, 20 mM NaAc, 10 mM EDTA 
Mounting medium for IF 90% glycerol in PBS  
Neutralization buffer mini prep 3M KaAc, 5M acetic acid, pH 5.5 
Nondenaturing loading buffer (6x)  
10mM Tris (pH 8), 1mM EDTA, 15% (w/v) Ficoll 400, 
0,25% bromophenol blue  
Paraformaldehyde (PFA)  4 g paraformaldehyde in PBS, pH 7.4 
PBS (1x) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2mM 
KH2PO4, pH 7.1-8.0 
PBS-Triton  1x PBS (see above), 0.5% TritonX-100 
Polysome lysis buffer 
15 mM Tris-HCl, pH 7.4, 15 mM MgCl2, 300mM 
NaCl, 1% Triton X-  ȕ-mercaptoethanol, 
200 U/ml RNasin, 1 tablet/10ml Complete Mini 
protease inhibitor 
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RNA gel extraction buffer 
300 mM sodium acetate, 1mM EDTA, 0.25% (w/v) 
SDS 
RNA loading buffer 
50% formamide, 2.2 M formaldehyde, 1x MOPS, 1% 
Ficoll, 0.04% bromophenol blue  
SSC (20x) 3 M NaCl, 0.3 M Sodium Citrate; pH 7.0  
Staining buffer for IF 10% Heat-inactivated goat serum (Gibco) in PBS 
TAE (1x) 40 mM Tris, 1 mM EDTA, 19 mM acetic acid  
TBE (1x) 89 mM Tris, 89 mM boric acid, 2 mM EDTA 
TE 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
TFB1 
50 mM MnCl2, 100 mM RbCl, 30 mM CaCl2, 15% 
Glycerol, pH 5.8 with 0.2N acetic acid  
TFB2 
10 mM MOPS pH 7.0, 10 mM RbCl, 75 mM CaCl2, 
15% Glycerol 
IF: immunofluorescence 
  
5.12 Consumables  
 
Consumable  Company 
0.5, 1.5 and 2 ml reaction tubes Eppendorf 
15 and 50 ml Falcon tubes TPP 
Cell culture plates and flasks TPP 
Microscopy glass slides Medco 
Coverslips Menzel 
Syringe-driven sterile filter unit (0.45 µm) Merck Millipore 
Cryo.S Freezing tubes  Greiner Bio-One 
Scalpel No 10 Feather 
20 Gauge syringe-needle TERUMO 
Syringe (virus supernatant filtration) TERUMO 
Syringe (DNA gel extraction) Braun  
MicroAmp 96-well Rxn Plate Applied Biosystems 
Cuvettes semi-micro Greiner-Bio 
96-well flat clear bottom plates Corning 
Incorporated 
11x60 polyallomer tubes Beckman Coulter 
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5.13 Equipment  
 
Equipment  Company 
Beckman Coulter Optima LE-80K Ultracentrifuge 
with SW60 rotor 
Beckman Coulter 
Biometra standard power pack P25   Biometra 
BioPhotometer Eppendorf 
CO2 incubator, HERAcell 150 Thermo Scientific 
Electrophorese MiniProtean Bio-Rad 
Hoefer miniVE (vertical electrophoresis system) Amersham Biosciences 
Leica DM5000B Microscope Leica 
Megafuge Heraeus 16R centrifuge Thermo Scientific 
Nanodrop 2000 Thermo Scientific 
Pico17 Heraeus centrifuge Thermo Scientific 
RC5C Centrifuge (Sorvall) ThermoScientific 
Roller RM5 CAT  
StepOnePlus RT-qPCR machine Applied Biosystems 
Teledyne Isco Foxy Jr. Gradient fractionator Axel Semrau 
Thermocycler PTC-200 MJ Research 
Thermomixer F1.5 Eppendorf  
UV gel documentation station UVP 
UV transilluminator (UV box) Bio View 
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5.14 Software 
 
Software  Version 
Graphpad Prism Version 6.0c, March 21, 2013 
IGV Version 2.3.25(29); 11/25/2013 
ImageJ 1.47v 
Leica Application Suite  10 (X) 
MacVector Version 11.1.1, 2011 
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6. Methods 
 
6.1. Eukaryotic experimental system 
 
6.1.1. Culture conditions & maintenance  
Mammalian cells were maintained in RPMI-1640 medium supplemented with 10% 
FBS. Primary B lymphocytes were cultured in RPMI-1640 medium supplemented 
with 20% FBS until lymphoblastoid cell lines (LCLs) grew out.  
All cells were cultured in a 37°C incubator at 100% humidity and 5% CO2 levels. 
LCLs were split 1:5 or 1:10 twice a week. The frequency depended on their growth 
rate.  
Adherently growing cell lines such as the HEK293 and HEK293 cell lines stably 
transfected with recombinant EBV (producer cells) were split before the culture plates 
reached confluency. The culture medium was removed, the cells were rinsed gently 
once with 1x PBS and incubted with 700 µl 0.05% Trypsin at 37°C for 1 min. The 
cells were then resuspended in RPMI/10%FBS. HEK293 cells were split 1:10. The 
producer cells were split 1:5.  
 
6.1.2. Freezing and thawing cells 
In order to freeze cells 1x106 LCLs or a 10 cm culture dish of adherent cells were 
detached and spun down for 10 minutes at 1200 rpm. Following removal of the 
supernatant the cell pellet was resuspended in 900 µl of RPMI medium containing 
20% FBS and transferred into a cryotube with pre-aliquotted 100 µl of DMSO. Cells 
were frozen in a -80°C freezer overnight and then transferred into liquid nitrogen-
containing containers for long-term storage.  
 
6.1.3. Induction of producer cells lines into virus production  
Producer cell lines were induced to produce infectious virus by transfecting plasmids 
encoding the viral transactivator BZLF1 (encoded on the p509 plasmid) and viral 
glycoprotein gp110 (encoded on the pRA plasmid) using 3 µl of Metafectene 
transfection reagent/1µg of DNA according to manufacturer’s instructions. The cells 
were first seeded onto 6 well plates at a cell density of 2.5x105 cells/well. After 
allowing the HEK293 producer cells to attach to the bottom of the plate overnight the 
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cells were transfected with 0.5 µg of each plasmid in 200 µl RPMI medium not 
containing any supplements. The medium was changed 24 h after transfection and 
virus was harvested 72 h after medium change and filtered through a 0.45 µm filter.  
 
6.1.4. Isolation of primary B lymphocytes 
Human whole blood was centrifuged in a beaker with 1x PBS supplemented with 100 
U/ml Heparin and underlayed with 50 ml Ficoll. The samples were spun at 1800 rpm 
for 30 min at room temperature and the upper Ficoll layer was carefully removed 
after centrifugation. The interphase was collected comprising approximately 30 to 40 
ml and was divided into two 50 ml Falcons. The interphase solution containing the 
buffy coat was filled to 50 ml with 1x PBS. The samples were spun at 1600 rpm for 
10 min at room temperature and the pellet was washed with 50 ml 1x PBS. The 
samples were spun down at 1400 rpm and the resulting pellet was washed with 50 
ml 1xPBS. Again the samples were spun down, this time at 1200 rpm for 10 min at 
room temperature. The pellets from the two falcons were combined and resuspended 
in 20 ml RPMI supplemented with 1% FBS. The cells were counted at a 1:20 dilution. 
The peripheral blood mononuclear cells (PBMCs) were diluted to a concentration of 
2x107 cells/ml in RPMI/1%FBS. Approximately 5% of PBMCs are estimated to 
constitute B cells. From the total number of PBMCs the B cell number was estimated 
and a ratio of 1:4 of B cells to CD19 Dynabeads was used for B cell isolation. The 
CD19 Pan B Dynabeads were transferred into 15 ml Falcons and washed three times 
with 5 ml RPMI/1% FBS by resuspending the beads, placing the Falcon tubes in a 
magnetic rack and removing the wash solution while taking care not to disrupt the 
beads on the side of the tube. Following washing the beads were mixed with the 
PBMCs and were incubated for 30 min at 4°C with gentle rolling. The beads were 
then washed again three times in 5 ml RPMI/1%FBS, again by using a magnetic 
rack. Finally, the beads were resuspended in 5 ml RPMI/1%FBS and the total 
number of cells was determined. For 1x106 cells 10 µl of CD19 Detachabeads were 
used to detach the isolated B cells from the CD19 Pan B Dynabeads. The samples 
were incubated for 45 min at room temperature by rolling. The samples were then 
placed in a magnetic rack and the supernatant was collected containing the B cells. 
The Falcons containing the Dynabeads were washed two more times with 5 ml 
RPMI/1%FBS and the supernatant was collected. The supernatants were pooled and 
spun for 5 min at 1200 rpm at room temperature. The resulting pellet was washed 
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once with 5 ml RPMI/1% FBS and resuspended in 5 ml RPMI supplemented with 
20% FBS.  
 
6.1.5. Infection of primary B lymphocytes and generation of LCLs  
B cells were incubated with virus supernatants with a multiplicity of infection of 20 at 
room temperature for 2 h with gentle shaking. The cells were then spun down at 
1200 rpm for 5 min and resuspended in 200 µl RPMI/20%FBS. Cells were cultured in 
U-bottom 96 well plates until LCLs grew out. They were then transferred into culture 
flask and were cultured in RPMI/10% FBS.  
 
6.1.6. Dual luciferase reporter assays  
For luciferase activity measurements HEK293 cells were seeded at a cell density of 
1x104 cells/well on 24 well plates in 500 µl complete RPMI medium. After 24 hours 
200 ng of plasmid with the different viral 5’leaders cloned in front of the Firefly 
luciferase gene were co-transfected with 200 ng of Renilla luciferase encoding 
plasmid and 1.5 µl Metafectene in a total volume of 50 µl of RPMI medium without 
any supplements. The Metafectene-DNA mixture was incubated at room temperature 
for 20 min before adding the mixture dropwise to the cells. Twenty-four hours later 
cells were washed once with 1x PBS and lysed in 100 µl Passive lysis buffer from the 
Dual-Luciferase Reporter Assay kit from Promega. Lysis was carried out at room 
temperature for 15 minutes with gentle shaking. Luciferase measurements were 
performed according to manufacturer’s instructions. Firefly luciferase activities were 
normalized to co-transfected Renilla luciferase activity measured sequentially. This 
was done to correct for differences in transfection efficiency between samples.  
 
6.2. Prokaryotic experimental system 
 
6.2.1. Culture conditions  
Bacteria were grown in LB medium with shaking or on LB Agar-containing plates to 
obtain single cell clones. Relative to the antibiotic resistance gene encoded on the 
plasmid, bacteria were culture in LB medium or LB agar supplemented with 
DQWLELRWLFV '+Į EDFWHULD ZHUH JURZQ DW &  
Glycerol stocks were prepared in 10% glycerol of bacteria cultured in exponential 
growth phase and frozen at -80°C for long-term storage.  
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6.2.2. Preparation of chemically competent bacteria  
2YHUQLJKW FXOWXUHV RI '+Į ZHUH LQRFXODWHG DQG JURZQ DW & 7KH FXOWXUH ZDV 
diluted 1:50 the following day in 400 ml LB medium. The bacteria were grown until an 
optical density of OD600nm= 0.4 was reached. The bacteria were then spun down at 
4000 rpm for 15 min at 4°C and resuspended in 50 ml ice-cold TFB1 buffer and 
transferred into fresh tubes. The samples were then spun down at 3000 rpm for 10 
min at 4°C. The pellet was resuspended in a final volume of 10 ml of ice-cold TFB2 
buffer. 300 µl aliquots were prepared and shock frozen on dry-ice/ethanol and were 
stored at -80°C until further use.  
 
6.2.3. E.coli transformation by heat-shock 
Chemically-FRPSHWHQW '+Į ZHUH WKDZHG RQ LFH PL[HG ZLWK '1$ and incubated 
on ice for 5 min. The bacteria were then incubated at 42°C for 2 min and transferred 
back to ice for 5 min. Finally 1 ml LB medium was added to the bacteria and they 
were cultured for 1 h at 37°C with shaking. After 1 h the bacteria were spun down at 
4000 rpm for 10 min and the pellet was resuspended in 50 µl LB medium and plated 
on LB agar plates with appropriate antibiotics. The plates were incubated over night 
at 37°C and single colonies were picked for further analysis. 
 
 
6.3. Working with DNA 
 
6.3.1. Cloning of overexpression plasmids  
Synthesis of selected transcript leader sequences was performed by Eurofins 
Germany (http://www.eurofins.de/de-de.aspx). The sequences were delivered cloned 
into pEX-A2 vectors. The sequences were excised from these vectors with the 
restriction enzymes HindIII and Bsp120I. The sequences were then ligated into 
corresponding restriction sites in the pGL4.5[Fluc/CMV/Amp] vector placing the 
synthesised transcript leader sequences upstream of the Firefly luciferase gene. 
Verification was performed by restriction enzyme digestion and sequencing of the 
cloned region.  
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Cloning procedure in detail: 
  
(1) Restriction enzyme digestion  
10 µg of DNA was digested with approximately 30 units (U) of each restriction 
enzyme for 3 hours at 37°C in a final volume of 100 µl.  
Following digestion 20 µl of 10x dephosphorylation buffer and 1U of alkaline 
phosphatase was added to the reaction tubes containing vector DNA and filled up to 
200 µl. The samples were incubated for an additional hour at 37°C.  
 
(2) Fragment and vector purification from agarose gels  
After restriction enzyme digestion all samples were run on a 0.8% agarose 
gel and a gel extraction of vector DNA and insert fragments was 
performed.  
See section 2.5.1 for details on the procedure.  
 
(3) Ligation reaction 
Ligation reactions were set up so that the molar ratio of vector DNA to insert 
DNA was approximately 1:3. Four units of T4 DNA ligase were used per 
reaction in a total volume of 10 µl. The ligation reactions were incubated for 1 
hour at room temperature and were subsequently used to transform 50 µl of 
chemically-FRPSHWHQW '+Į (FROL XVLQJ WKH KHDW-shock method. Alkaline 
miniprep analysis was used to screen for correct clones. 
 
6.3.2. Extraction of DNA with Phenol:Butanol  
 
From agarose gels  
Generally 0.8% agarose gels containing ethidiumbromide were run at 100 V for 
approximately an 1 hour. The desired DNA fragments were then cut from the gel 
using a UV box to visualize the DNA bands in the gel. A clean scalpel was then used 
to slice out the desired DNA fragments from the gel. The gel slice was then squeezed 
through a 20 gauge syringe-needle. To the gel slurry 1 gel volume of phenol was 
added and the samples were vortexed. The tubes containing the phenol-gel slurry 
were then places on dry ice for 5 min until the mixture was frozen and thawed in a 
37°C water-bath. The freeze-thaw cycles were repeated twice more. The frozen gel-
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slurry samples were subsequently centrifuged at 12000 rpm for 30 min at room 
temperature. The upper phase of the centrifuged samples was collected and mixed 
with 1 volume of 1-butanol. The samples were vortexed for at least one minute and 
centrifuged at 12000 rpm for 10 min at room temperature. The upper phase was 
discarded and the lower phase was collected and DNA was precipitated with 1/10 
volume of sodium acetate and 2.5 volumes of ethanol. Precipitations were carried out 
for 1 hour in a -20°C freezer. Subsequently the samples were spun at 13000 rpm for 
30 min. The DNA pellet was then washed with 1 ml of 70% ethanol followed by a 5 
min centrifugation step at 13000 rpm. The DNA was then resuspended in 30 µl TE 
buffer. DNA purity and concentration were determined by Nanodrop.   
 
In solution  
DNA isolation from solutions were performed by adding 1 volume of phenol to the 
DNA solutions and vortexing for 1 min. The samples were then centrifuged for 10 min 
at room-temperature at 13000 rpm. The upper phase was collected and transferred 
to a fresh tube. 1 volume of 1-butanol was added, vortexed for 1 min and spun at 
13000 rpm for 5 min at room-temperature. The upper phase was discarded and the 
lower phase into a fresh Eppendorf tube. The DNA was precipitated with 2.5 volumes 
of ethanol and 1/10 volume of 3M sodium acetate (pH 5.0). The precipitates were 
incubated for 20 min at -20°C and were subsequently spun at 13000 rpm for 20 min 
at room-temperature. The pellet was washed in 70% of ethanol to remove salts with 
5 min centrifugation at 13000 rpm. The washed DNA pellet was resuspended in 1xTE 
buffer. DNA purity and concentration were determined by Nanodrop.   
 
6.3.3. Plasmid DNA isolation (Mini & Midi preparation) 
 
Miniprep 
Single E.coli colonies were plated out on a ! of a LB agar plate with appropriate 
antibiotics and grown overnight at 37°C depending on the clones analysed. Bacteria 
were scraped off and resuspended in 200µl TE buffer containing  concentration 
RNase A. Bacteria were lysed by addition of 200µl of lysis buffer (add components to 
materials), inversion of the samples and incubation for 5min at room temperature. 
Lysates were then neutralized with 200µl neutralization followed by 10min incubation 
on ice. The lysates were then cleared by centrifugation at 13 000rpm for 10min. The 
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supernatant was transferred into fresh tubes containing 500µl Isopropanol. 
Precipitations were carried out for 10min on ice and DNA was pelleted for 10min at 
13 000rpm. The DNA pellet was washed with 1ml 70% Ethanol and were dissolved in 
TE followed by restriction enzyme analysis. Correct colonies were inoculated in 
200ml of LB medium for midiprep analysis.  
 
Midiprep 
E.coli cell containing the desired plasmids were inoculated from glycerol-stock into 
200 ml if LB medium supplemented with ampicillin (100 µg/ml). Bacteria were grown 
at 37°C overnight with gentle shaking. The following day bacteria were centrifuged at 
4000 rpm for 15 min at room-temperature. The supernatant was discarded and the 
bacterial pellet resuspended in 4 ml of resuspension buffer from the Jetstar Midiprep 
kit. The resuspended cells were transferred to fresh tubes. 4 ml of lysis buffer were 
added and mixed with the samples by gentle inversion. Samples were incubated at 
room-temperature for 5 min. Lysis was neutralized by adding 4 ml of neutralization 
buffer 3. The samples were inverted 3-4 times and incubated on ice for 10 min. 
Lysates were then centrifuged for 10 min at 12000 rpm at room-temperature. The 
supernatant was filtered through a fluted filter and the Jetstart column was 
equilibrated with 10 ml equilibration buffer E4 in parallel. The filtered lysate was then 
loaded on the column. The column was allowed to empty by gravity flow and was 
washed twice with 10 ml wash buffer E5. The DNA was eluted from the column with 
5 ml of elution buffer E5 into fresh Falcon tubes. The eluted DNA was mixed with 0.7 
volumes of isopropanol and centrifuged for 30 min at 4°C at 4000 rpm. The 
supernatant was discarded. The DNA pellet was resuspended in 1 ml of 80% ethanol 
and transferred into a fresh 1.5 ml Eppendorf tube. The samples were centrifuged at 
13000 rpm for 5 min at room-temperature. Ethanol was discarded and the pellet was 
resuspended in 400 µl TE buffer. DNA purity and concentration were determined by 
Nanodrop.  Plasmid integrity was analysed by agarose gel electrophoresis.  
 
6.3.4. Quantitative real-time PCR (qRT-PCR)  
 
Taqman qRT-PCR for virus titer determination  
To determine the virus titers from virus supernatants of induced producer cell lines 
50µl of virus supernatant was transferred into a PCR tube and 1U of DNase I was 
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added. The samples were incubated in a thermocycler for 60min at 37°C followed by 
DNase inactivation for 10 min at 70°C. Afterwards 5 µl of DNase-treated 
supernatants was transferred into a fresh PCR tube and mixed with 5 µl of 1:100 
diluted Proteinase K (10 mg/ml). The samples were again incubated in a 
thermocycler for 60 min at 50°C followed by Proteinase K inactivation for 20 min at 
75°C. Finally the samples were diluted 1:10 in H2O and 5µl were used for qPCR 
measurements.  
 
qRT-PCR reaction mix: 
12.5 µl Taqman 2x Universal Mastermix 
2.5 µl EBV polymerase forward primer (10 µM) 
2.5 µl EBV polymerase reverse primer (10 µM) 
1 µl FAM-labeled EBV polymerase probe (20 µM)  
1.5 µl H2O   
 
Cycling conditions were as follows:  
 1 50°C  2 min 
 2 95°C  10 min 
 3 95°C  15 sec 
 4 60°C  1 min 
steps 3 and 4 were run for 40 cycles 
 
SYBR Green qRT-PCR for gene expression analysis  
SYBR Green qRT-PCR was used to determine RNA transcript abundance for viral 
genes. RNA was extracted from cells directly or from fractioned gradients from 
polysome profiling experiments (see RNA chapter for details on RNA purification). 
RNA was reverse transcribed into cDNA (see RNA chapter for detailed protocol). 5µl 
of cDNA were used for measurements.  
 
qRT-PCR reaction mix:   
10 µl SYBR Green master mix  
0.4 µl forward primer (10 µM) 
0.4 µl reverse primer (10 µM) 
4.2 µl H2O 
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Cycling conditions were as follows:  
 1 95°C  10 min 
 2 95°C  15 sec 
 3 60°C  1 min 
steps 2 and 3 were repeated for 40 cycles 
 
 
6.4. Working with RNA  
 
6.4.1. RNA extraction from cell pellets 
RNA extractions from cell pellets were performed with Trizol reagent. Cell pellets 
were resuspended in 1 ml Trizol reagent for cell lysis. 200 µl of chloroform were 
added/1 ml Trizol lysate. Samples were shaken vigorously for 30 sec and incubated 
at room-temperature for 3 min. Subsequently the samples were spun at 12000 rpm 
for 15 min at 4°C. In the mean time 500 µl of isopropanol were aliquotted to fresh 15 
ml Eppendorf tubes. The upper phase of the samples (approximately 600 µl) was 
then collected and transferred to the isopropanol-containing tubes. Samples were 
mixed by inverting and incubated for 2 h at -80°C. In the mean time RNase-free 
water was heated to 95°C. After 2 h of precipitation at -80°C the samples were spun 
at 12000 rpm for 10 min at 4°C. Isopropanol was removed carefully and 75% ethanol 
prepared with RNase-free water was used to wash the pellet. The samples were 
centrifuged at 8000 rpm for 5 min at 4°C. The RNA pellet was resuspended in 50 µl 
pre-heated RNase-free water.  
 
6.4.2. RNA extraction from sucrose solutions after polysome profiling  
RNA extractions from polysome fractionation in sucrose solution were performed by 
mixing equal volumes of fraction with ready-to use phenol:chloroform:isoamyl alcohol 
(25:24:1) mix. Samples were shaken for 30 sec and spun at 12000 rpm for 15 min at 
4°C. After centrifugation the upper phase was transferred into fresh 1.5 ml Eppendorf 
tubes. 500 µl of isopropanol was added and samples were mixed by inversion. 
Precipitations were carried out at -80°C for 2 h. In the mean time RNase-free water 
was heated to 95°C. After 2 h of precipitation at -80°C the samples were spun at 
12000 rpm for 10 min at 4°C. Isopropanol was removed carefully and 75% ethanol 
prepared with RNase-free water was used to wash the pellet. The samples were 
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centrifuged at 8000 rpm for 5 min at 4°C. The RNA pellet was resuspended in 20 µl 
RNase-free water.  
  
6.4.3. Reverse transcription of RNA 
The cDNA synthesis was prepared from total RNA extracted from cell pellets or from 
RNA purified from fractioned gradients. 1 µg of RNA in a final volume of 14.4 µl was 
pipetted into a clean 0.5 ml PCR tube. The sample was heat denatured at 90°C for 3 
min and transferred onto ice immediately after.  
5.6 µl of master mix containing:  
  4 µl 5x RT buffer 
  0.4 µl 10 mM dNTPs 
  0.5 µl random hexamers 
0.2 µl RNasin 
0.5 µl AMV reverse transcriptase 
was added. The mixture was incubated for 10 min at 25°C followed by a 1 h 
incubation at 42°C. Subsequently heat inactivation was performed at 90°C for 5 min. 
The cDNA was diluted 16-fold with nuclease-free water. 5 µl of diluted cDNA was 
used in RT-qPCR measurements.  
 
6.5. Immunofluorescence analysis 
Cell for immunofluorescence analysis were washed twice with PBS, dropped on 
microscopy slides and left to air dry. After drying cells were fixed depending on the 
antibody either with 4% PFA for 20 min at room temperature or in acetone for also for 
20 min. PFA fixed cells were permeabilized in PBS with 0.5% Triton X-100 for 2 min. 
Incubation with the primary antibody was performed for 30 min at 37°C in a humidity 
chamber. Afterwards the slides were washed three times for 5 min in PBS. 
Incubation with the secondary Cy3-labeled antibody was carried out for another 30 
min at 37°C in a humidity chamber. Again, slides were washed three times in PBS for 
5 min. Nuclei were counterstained in DAPI solution for 1 min. Cover slips were 
mounted with 90% glycerol in PBS.  
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6.6. Polysome profiling 
 
6.6.1.  Preparation of linear sucrose gradients 
To prepare linear sucrose gradients for polysome and ribosome profiling 5 different 
sucrose solutions were prepared in polysome lysis buffer: 50%, 41.9%, 33.8%, 
25.6% and 17.5%.  
To pour the gradients first 790 µl of 50% sucrose solution was slowly pipetted into the 
bottom of a Beckman polyallomer tube. The tube was covered with aluminum foil and 
frozen for 20 min at -80°C. The frozen 50% sucrose was carefully overlayed with 
790µl of 41.9% sucrose solution. Again the tubes were covered with aluminum foil 
and frozen for 20 min at -80°C.  This procedure was continued until all the sucrose 
solutions were frozen on top of one another, ending with 17.5%.  
Gradients were stored at -80°C until use. The night before polysome or ribosome 
profiling experiments the gradients were transferred into the 4°C room to thaw.  
 
6.6.2. Preparation of cells for ultracentrifugation  
Prior to profiling LCLs were expanded to large culture flasks. The cells were split 1:3 
48 hours prior to profiling. On the day of the profiling experiment the LCLs were then 
diluted 6x105 cells/ml and left in the incubator for another 1.5 hours. A total of 3x107 
cells were used per profiling experiment. For profiling LCLs were treated with 
100µg/ml cycloheximide for 5 minutes to stall ribosomes on RNA. Cell were then 
centrifuged at 4°C for 5 minutes at 1500 rpm. Supernatant was removed and LCLs 
were lysed in 300 µl polysome lysis buffer. Lysates were incubated for 10 minutes at 
4°C on a roller. Afterwards nuclei were removed by centrifugation at 10000 rpm for 
10 minutes at 4°C. The resulting supernatant was loaded onto a linear sucrose 
gradient. Ultracentrifugation was run at 4°C at 35000 rpm for 2.5 hours in an SW60Ti 
rotor.  
 
6.6.3. Gradient fractionation 
Following centrifugation the gradients were fractioned using a Teledyne Isco Foxy Jr. 
Gradient fractionator. The device separated the gradient into 12 fractions containing 
400µl of sucrose gradient. RNA was purified from the single fractions using organic 
solvent extraction followed by isopropanol precipitation.  
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6.7. Ribosome profiling 
 
6.7.1. Generation and purification of ribosome protected fragments (RPFs) 
Ribosome profiles were generated according to a modified protocol from Ingolia et 
al4. LCLs were prepared according to the polysome profiling protocol (see section: 
Polysome profiling). In addition to treatment with cycloheximide samples that were 
prepared for open reading frame identification were incubated for 2 or 5 min with 2 
µg/ml harringtonine at 37°C prior to addition of 100 µg/ml cycloheximide for another 5 
min. The cells were then transferred into a falcon tube and centrifuged for 5 min at 
4°C at 1200 rpm. The pellet was lysed with 300 µl ice-cold polysome lysis buffer and 
ultracentrentrifuged and fractioned as described in the polysome profiling protocol. 
Fractioned samples were treated with 640U RNase I per 1 OD A260 for 15min on a 
roller at room temperature. RNA was purified with phenol:chloroform:isoamyl alcohol 
as described in section 6.4.2. with a slight modification: Precipitations were carried 
out at -80°C overnight and the recovered RNA was resuspended in 5 µl of 10mM 
RNase-free Tris (pH 8).  
 
6.7.2. RNA size selection  
RPFs were size-selected by polyacrylamide gel electrophoresis using a pre-cast 15% 
polyacrylamide TBE-urea gel. Samples were mixed with 5 µl of 2x denaturing loading 
buffer and were run with synthesized control oligonucleotides of 26 and 34 nt size 
and a 10 bp DNA ladder. The samples were denatured at 80°C for 90 sec. The gel 
was run for 65min at 200 V and was subsequently stained with 1:20000 dilution of 
SYBR Gold dye in 1x TBE buffer for 5 min. The region on the gel was excised that 
was demarcated by the two control oligonucleotides ranging from 26 to 34 nt. The gel 
slices were transferred into a fresh RNase-free tube. Additionally the marker 
oligonucleotides were also excised as internal control. To the gel slices 400µl RNA 
gel extraction buffer was added and the samples were frozen for 30min on dry ice. 
The samples were then left on a roller overnight at room temperature.  
The following day the RNA was precipitated with 1.5 µl GlycoBlue and 500 µl 
isopropanol. The samples were placed into the -80°C freezer for 2h and were then 
spun at max speed for 30min at 4°C. Size-selected RNA was then resuspended in 
10µl 10mM Tris (pH 8) and transferred to a fresh RNase-free tube.  
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6.7.3. Dephosphorylation & linker ligation 
For the dephosphorylation reaction 33 µl of RNase-free water was added to the 10 µl 
of resuspended, size-selected RNA. The samples were then denatured for 90sec at 
80°C and left to equilibrate to 37°C.  
The following reaction was then set up (50 µl final volume):  
1x T4 PNK buffer  
20U RNasin  
10U T4 PNK  
The reaction was incubated at 37°C for 1h and the enzyme was then heat-inactivated 
for 10 min at 70°C.  
RNA was precipitated by addition of 39 µl water, 1 µl GlycoBlue, 10 µl 3M sodium 
acetate and 150 µl isopropanol. The samples were placed into the -80°C freezer for 
2h and were then spun at max speed for 30min at 4°C. Dephosphorylated RNA was 
resuspended in 8.5 µl 10mM Tris (pH 8) .  
To the 8.5 µl of dephosphorylated RNA 1.5 µl of preadenylated linker from the 
Universal miRNA cloning linker kit were added and denatured at 80°C for 90sec and 
then let to cool to room temperature.  
 
The following linker ligation reaction was set up (20µl final volume):  
1x T4 Rnl2 buffer 
15% (w/v) PEG 8000  
20U RNasin  
200 U T4 Rnl2(tr) 
 
The reaction was incubated at room temperature for 2.5h. After linker ligation 338 µl 
of RNase-free water were added to the reaction and precipitated with 40 µl 3M 
sodium acetate, 1.5 µl GlycoBlue and 500 µl isopropanol. The samples were placed 
into the -80°C freezer for 2h and were then spun at max speed for 30 min at 4°C. 
The ligation reactions were separated by polyacrylamide gel electrophoresis as 
described in the size-selection section of the protocol.  
The ligation products were excised from the gel as demarcated by the ligated marker 
oligos. RNA was recovered again in 400µl RNA gel extraction buffer as described in 
the size-selection section of the protocol.  
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After isopropanol precipitation the ligated RNA was resuspended in 10µl 10mM Tris 
(pH 8).   
 
6.7.4. Reverse transcription  
To the ligated RNA 2 µl of reverse transcription primer (1.25 µM) was added and 
denatured for 2 min at 80°C. The samples were then immediately transferred on ice. 
A thermal cycler was pre-warmed to 48°C.  
The following reverse transcription reaction was set up (20 µl final volume):  
 
1x first strand buffer  
0.5 mM dNTPs 
5 mM DTT 
20U RNasin  
200U SuperScript III  
 
The reaction mixture was incubated for 30min at 48°C. RNA was then hydrolysed by 
the addition of 2.2 µl of 1N NaOH and incubation for 20min at 98°C. The cDNA was 
then precipitated by addition of 20 µl 3M sodium acetate, 2 µl GlycoBlue, 156 µl 
water and 300 µl isopropanol. The samples were placed into the -80°C freezer for 2h 
and were then spun at max speed for 30min at 4°C and resuspended in 10 µl 10mM 
Tris (pH 8). Precipitated cDNA was further separated from unextended primer by 
polyacrylamide gel electrophoresis as described in the size-selection section of the 
protocol. As a control 10 µl of reverse transcription primer at 1.25 µM concentration 
was prepared and run with the samples. The reverse transcribed product was 
excised from the gel and transferred into a fresh tube. The cDNA was extracted with 
400 µl DNA gel extraction buffer. The gel slice in the buffer was frozen on dry ice for 
30 min and was then transferred onto a roller at room temperature overnight. The 
eluted cDNA was precipitated as described in the size-selection section of the 
protocol. Precipitated cDNA was resuspended in 15 µl 10mM Tris (pH 8) and 
transferred to a PCR tube.  
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6.7.5. Circularization  
The circularization reaction was prepared as following (20 µl final volume):  
1x CircLigase buffer 
50mM ATP 
2.5mM MnCl2 
100U CircLigase 
The reaction mixture was incubated at 60°C for 1 h.  
 
6.7.6. Depletion of rRNA  
For rRNA depletion 5 µl of circularized cDNA was mixed with 1 µl of subtraction oligo 
mix, 1 µl 20x SSC and 3 µl water. The mix was denatured at 100°C for 90 sec and 
then an annealing reaction was setup at 0.1°C/s to 37°C. Once the thermocycler 
reached 37°C the samples were incubated for 15min.  
In the mean time MyOne Streptavidin C1 DynaBeads were vortexed and 25µl of the 
beads was used per subtraction reaction. The beads were aliquotted to a fresh tube 
and washed three times using a magnetic rack in 1x bind/wash buffer. After the final 
wash the beads were resuspended in 10 µl/subtraction reaction in 2x bind/wash 
buffer. The beads were transferred to 37°C and the samples form the thermocycler 
were directly transferred to the beads. The mix was incubated for 15min at 37°C with 
vigorous shaking. After the incubation time the samples were directly transferred to 
the magnetic rack and beads were isolated for 1min at a time on the rack. 17.5 µl if 
eluate was recovered from the rRNA depletion procedure and transferred to a fresh 
tube. The depleted cDNA was recovered by precipitation with 2 µl GlycoBlue, 6 µl 5M 
NaCl, 74 µl water and 150 µl isopropanol. DNA was frozen at -80°C for 2 h and spun 
at 13000 rpm for 30 min at 4°C. The recovered cDNA was resuspended in 5 µl 10mM 
Tris (pH 8).  
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6.7.7. PCR amplification and barcoding 
To the 5 µl of cDNA 95 µl of following master mix was added:  
 20 µl 5x Phusion HF buffer  
 2 µl 10 mM dNTPs  
0.5 µl forward library primer 
0.5 µl reverse indexed primer* 
71 µl RNase-free water 
1 µl Phusion polymerase (2U/µl) 
*A different indexing primer was used for each sample.  
 
The 100 µl reaction was divided up into five 16.7 µl aliquots. PCR amplification was 
performed with varying cycle numbers. The five tubes containing the samples were 
placed into a thermal cycler and following cycling conditions were used:  
   
 
  steps 2-4 were run for 18 cycles  
 
Following cycling 3.3 µl of 6x nondenaturing loading dye was added to each tube and 
the samples were run on an 8% polyacrylamide nondenaturing gel. The gel was run 
for 40 min at 180 V. The gel was then stained in 1x SYBR Gold prepared in 1x TBE 
buffer. The bands were visualized by placing the gel on a UV box. A product band of 
approximately 175 nt size was excised from the gels. The gel slices were placed into 
1.5 ml Eppendorf tubes and the PCR amplification products were recovered by 
adding 400 µl of DNA gel extraction buffer to each gel slice. The gel slice in the buffer 
was frozen on dry ice for 30 min and was then transferred onto a roller at room 
temperature overnight. The eluted cDNA was precipitated as described in the size-
selection section of the protocol. Precipitated cDNA was resuspended in 15 µl 10mM 
Tris (pH 8) and transferred to a PCR tube. 
 
  
step temperature duration 
1 98°C 30 sec 
2 98°C 10 sec 
3 65°C 10 sec 
4 72°C 5 sec 
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6.7.8. Sequencing  
The samples were sequenced at the Genomics and Proteomics Core Facility of the 
DKFZ on a HiSeq V3 sequencer from Illumina.  
 
 
6.8. Bioinformatics 
 
6.8.1. Read alignment & normalization  
Adaptor sequences were trimmed with FastX clipper. STAR was used for the 
alignment. First, reads mapping to rRNA sequences were removed and then aligned 
to the human genome issue HG-19 as well as to the corresponding viral genomes 
B95-8 (accession number NC_007605.1) and M81 (accession number KF373730.1).  
Read lengths of sequenced reads were determined with Fastq.  
Reads were normalized in two ways depending on the read origin. For RPFs derived 
from cellular transcripts a scaling factor was calculated. The scaling factor is the ratio 
between the total number of reads in M81-infected LCLs to those in B95-8-infected 
LCLs. The absolute RPF counts were then multiplied by this scaling factor. RPF 
densities were calculated as reads per kilobase of coding DNA sequence.  
This normalization method is not suitable for the low number of reads that mapped to 
the viral genome. Total count normalization described by Dillies et al.5 was used to 
compare RPF densities on viral transcripts instead. Here, absolute RPF counts were 
divided by the number of uniquely mapped reads that aligned to the viral genome in 
the respective libraries.  
 
6.8.2. Metagene analysis  
To analyse the aggregation of reads around start and stop codons (metagene 
analysis) the reads of 27 and 28 nt length were considered. Reads of this length 
were counted on transcripts and were normalized by transcript length. Transcripts 
with an average length of > 2 were considered for analysis. Average read depth of 
nucleotide positions 20 bases up- and downstream of start and stop codons was then 
calculated.  
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6.8.3. Identification of translation initiation sites  
Harringtonine-treated libraries were used to identify translation initiation sites. The 
machine learning approach described by Stern-Ginossar et al.6 was not reliable 
enough due to the low ribosome coverage of the viral genome. The identification of 
novel small viral ORFs was carried out by manual screening of the alignments in 
IGV. Putative ORFs were scored as translated when at least two of the three 
harringtonine-treated libraries from a strain were positive for it. The start codon within 
a peak was designated as the 15th nucleotide of reads with a length of 27-28 nt and 
the 16th if the reads were longer.  
Figures showing ribosome coverage were generated using the Sashimi Plot function 
in IGV.  
 
6.8.4. Calculation of ratios  
The out:in ratios were calculated by dividing the number of RPFs mapping within 
5’leaders of a transcript (out) by the number of RPFs mapping to the coding region of 
the transcript (in). An arbitrary count of 1 was added to both out and in counts.  Read 
coverage was length normalized by nucleotide length of the respective feature 
(5’leader and coding region). 
5’leader:AUG ratios were calculated by dividing the number of RPF mapping within 
the 5’leaders of a transcript by the number of RPFs mapping to the start codon of a 
transcript (AUG). An arbitrary count of 1 was added to both out and in counts. Read 
coverage was length normalized by nucleotide length of the respective feature 
(5’leader and AUG triplet). 
 
6.8.5. UORF conservation analysis  
Genome sequences of different EBV strains were downloaded from the NCBI 
database and genomic regions of interest were aligned against each other using 
MacVector software.   
 
6.8.6. IPA analysis  
Ingenuity pathway analysis (IPA) software from Quiagen was used to assess 
differentially regulated genes and the associated pathways and biological functions in 
the two strains. For the analysis the cycloheximide-derived data sets were used.  
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Transcript translation levels were first calculated by quantifying the read number per 
kilobase of coding sequence and normalizing with the median calculated over all 
transcripts. These expression values were loaded into the IPA software for analysis.   
 
6.9. Statistical analysis 
Fisher’s exact test was used to assess significance of results generated from IPA 
analysis. The Fisher’s exact test was performed with the IPA software.  
For all other analyses the unpaired t test was used to assess significance. Prism 
software was used for performing the unpaired t test. Where depicted, error bars 
represent standard deviations of the data.   
 
6.10. Work distribution 
I performed the generation of the ribosome profiles and all the associated wet-lab 
experiments. The pre-processing and alignment of reads from the sequenced 
libraries were done by Dr. Olaf Klinke. Quality control assessments were conducted 
by Dr. Agnes Hotz-Wagenblatt from the DKFZ Core Facility Genomics and 
Proteomics and by myself.  
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